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1 Introduction 
1.1 Definition 
Lower urinary tract symptoms (LUTS) refer to a group of urological symptoms 
which can be categorized into storage (syn. irritative) and voiding (syn. 
obstructive) symptoms. The voiding/obstructive symptoms include poor or 
intermittent stream, hesitancy, terminal dribbling, incomplete voiding, overflow 
incontinence and urinary retention (UR). The storage/irritative symptoms 
appear as increasing frequency or urgency of urination, nocturia, and could also 
be painful during urination (Gratzke et al., 2015).  
 
LUTS were once emphasized to be mainly caused by benign prostatic 
hyperplasia (BPH), however, recent studies found that LUTS were often not 
just related to BPH (Abrams, 1994; Chapple et al., 2008), and increased 
evidences indicated and clarified the understanding of the LUTS as a functional 
unit, and the multifactorial etiology could be responsible for associated and 
diverging symptoms. In fact, recent studies have demonstrated that bladder 
dysfunction including detrusor overactivity (DO) and detrusor underactivity 
(DU), functional or structural abnormalities of urinary tract and surrounding 
tissues may cause LUTS (Drake, 2014; He et al., 2016). In addition, some 
non-urological disorders such as metabolic syndrome may also represent 
etiologies of LUTS (Bergdahl et al., 1998; Koskimaki et al., 2001; McDonald 
et al., 2017). 
 
1.2 Epidemiology 
LUTS are common among both female and male patients, while prevalence 
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reported from epidemiological studies differed, ranging from 13% (Boyle et al., 
2003b) to 67% (Lee et al., 2011). It is widely accepted and indicated from most 
of studies that the prevalence of LUTS increases with age (Coyne et al., 2009; 
Irwin et al., 2006; Irwin et al., 2009; Irwin et al., 2011; Stewart et al., 2003). 
Nearly 10% of male and 11% of married females aged 40-49 years reported 
moderate or severe symptoms, while at the age of 70-79 years old, the 
percentages increased remarkably to 40% and 28% for male and female, 
respectively (Boyle et al., 2003b). Another recent study on male population 
also reported that 40% of men over the age of 40 complained of moderate to 
severe LUTS, and 70% of men above the age of 70 years, while the proportion 
of men suffered from LUTS increased to 90% in cohort over the age of 85 
years (Hollingsworth and Wilt, 2014). Older male population has a higher 
incidence of LUTS than older female (Boyle et al., 2003a; Irwin et al., 2011), 
approximately 2/3 of elderly men in a previous studied population reported to 
suffer at least one LUTS complaint (Garraway et al., 1991; Nielsen et al., 
1994).  
 
As the predicted aging of the worldwide population, the future worldwide 
prevalence is expected to increase accordingly. It was estimated that voiding 
symptoms will affect more than 600 million men in 2018 worldwide, which 
will cause high economic burden for the society (Irwin et al., 2011; MacKenzie 
and Aning, 2016; Taub and Wei, 2006). Regarding any LUTS, i. e. voiding and 
irritative symptoms, even around 1.5 billion in men, and 3.1 billion patients 
may be expected in 2018 for both genders (Irwin et al., 2011). 
 
1.3 Etiology 
Multifactorial etiology contributes to associated symptoms. It is widely 
accepted that aging might be one of the most important factors for LUTS 
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(Vahabi et al., 2017). Figure 1 shows several further potential causes of LUTS. 
Distal ureteric stones or stricture could cause partial obstruction in ureter 
during voiding, which is characterized by difficulty in voiding and reduced 
urine flow rate.  
 
BPH, which causes benign prostate obstruction (BPO) and bladder outlet 
obstruction (BOO), is responsible for symptoms such as dysuria, painful 
urination, hesitancy, straining, splitting and spraying, intermitted stream, 
terminal dribbling, incomplete voiding, overflow incontinence, feeling of 
incomplete emptying, post-micturition dribbling, and finally urinary retention 
(UR) (Abrams et al., 2002; Chapple, 2011). Altogether, voiding symptoms 
suggestive of BPH are caused and characterized by a lowered urinary flow 
(Qmax) (Roehrborn, 2008). It is widely accepted, that increased prostate size due 
to hyperplastic growth on the one hand, and an increased smooth muscle tone 
in the hyperplastic prostate may both cause compression of the urethra, which 
impairs bladder emptying and urinary flow and results in symptoms (Cioanta 
and Muschter, 2000; Guneyli et al., 2017; Hennenberg et al., 2014b; Oelke et 
al., 2015). 
 
In parallel or even in addition to LUTS suggestive of BPH, irritative symptoms 
due to overactive bladder (OAB) are common. These are caused by involuntary 
detrusor contractions, which will result in symptoms including increased 
daytime frequency, nocturia, urgency, urinary incontinence (Apostolidis et al., 
2017; Chapple, 2011; Izett et al., 2017; Lee and Kuo, 2017a). The origin of 
these contractions may be neurogenic, but may also include other factors such 
as spinal cord injury, prostate surgery or external radiation of prostate cancer 
(Kowalczyk, 2003). LUTS caused by chronic pelvic pain syndrome could 
present symptoms as dysuria, increased urgency of urination or painful 
urination but without evidence of urinary tract infection (Doggweiler et al., 
2017).  
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Bladder tumor that locates in bladder outlet might cause BOO and is 
characterized by increased detrusor pressure and reduced urine flow rate. 
Detrusor underactivity (DU) may also cause difficulties in voiding and chronic 
UR, what may be difficult to distinguish from BOO (Gratzke et al., 2015). 
 
Besides, some other diseases have been found to be risk factors for LUTS, for 
example, nocturnal polyuria, which is characterized by increased excretions of 
water and sodium during sleeping time but normal excretions in daytime. It is 
speculated that nocturnal polyuria and natriuresis are responsible for most 
nocturia in elderly men with LUTS (Matthiesen et al., 1996).  
 
Foreign body, most observed in bladder, have been reported to cause LUTS, 
and most of these patients might present urinary tract infection or painful 
urination (Bansal and Yadav, 2016). Besides, non-urogical disease such as 
Parkinson's disease (McDonald et al., 2017), drug abuse (Peng et al., 2014), 
metabolic disorders (Hammarsten and Peeker, 2011), and arthritis (Koskimaki 
et al., 2001) have been also suspected to associate with LUTS. 
 
INTRODUCTION	
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Figure 1: potential causes of LUTS (Gratzke et al., 2015). LUTS may be 
primarily caused by the prostate and the bladder. Other factors may cause 
LUTS as well, which need to be considered particularly during diagnosis of 
LUTS.  
 
1.4 The role of BPH in LUTS 
Although it becomes increasingly clear that BPH is not the single contributor to 
LUTS, it remains one of the most crucial factors. In fact, BPH could be 
observed in the majority of elder men and might then cause LUTS (Milani and 
Djavan, 2005). Considering the expected demographic transition in Western 
and Asian countries with a growing population of elderly men, the importance 
of LUTS suggestive of BPH will increase in the near future (Lepor, 2005).  
 
The age of initiation of the growth of BPH was estimated to be from 30 years 
and upwards. Nearly 50% of men >50 years old will present pathological 
evidence of BPH, and the percentage was supposed to increase to more than 80% 
in the groups of patients with an age of 80 years old or older (Berry et al., 
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1984). In fact, approximately every man at some point in his life will have 
LUTS secondary to BPH (Lepor, 2005). 
 
The pathophysiology of LUTS is considered to include BOO (bladder neck 
abnormity, hyperplastic prostate or urethral stricture), or bladder dysfunction 
(DU or DO) (Lee and Kuo, 2017b). The pathophysiology of BOO in men with 
BPH consists of static and dynamic factors (Lepor, 2005). The static 
obstruction means that the hyperplastic prostate may cause compression of both 
the urethra and bladder outlet which could result in increased resistance to 
urine flow (Hennenberg et al., 2014a). The dynamic obstruction is due to an 
increased tension of prostate smooth muscle, which causes obstruction of the 
urethra (Hennenberg et al., 2014b). 
 
It is widely recognized that activation of α1-adrenoceptors in the prostate 
causes smooth muscle contraction, which contributes to increases smooth 
muscle tone and BOO in BPH (Hennenberg et al., 2014b). Previous studies 
have reported that the density of α1-adrenoceptors was significant higher in 
prostate tissues from patients with BPH than those without (Ishigooka et al., 
1997; Kondo et al., 1993; Price et al., 1993; Walden et al., 1999), suggesting 
that enlarged prostates can reduce the urine flow rate via increased 
responsiveness to α1-adrenergic prostate smooth muscle contraction.  
 
It is widely accepted that the amount of prostate smooth muscle contributes to 
BOO, and that the improvement in LUTS suggestive of BPH by α1-blockers 
might be related to relaxation of prostate smooth muscle (Hennenberg et al., 
2014b; Lepor, 2005; Oelke et al., 2014). Consequently, α1-blockers are the first 
line option for treatment of LUTS suggestive of BPH (Hennenberg et al., 2014a; 
Oelke et al., 2012a). They will induce smooth muscle relaxation in the prostate 
and thereby reduce voiding symptoms. 
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1.5 Pharmacological treatment for LUTS 
1.5.1	Current	therapies	
α1-adrenoceptor antagonists (α1-blockers) 
α1-blockers are considered to be the medication showing fastest reduction of 
LUTS secondary to BPH. The current α1-blockers available for clinical use are 
tamsulosin, alfuzosin, terazosin, doxazosin, which are similar in overall clinical 
impact (Djavan et al., 2004a; Milani and Djavan, 2005). α1-blockers can reduce 
the prostate tone and BOO via inhibiting the effect of endogenously released 
noradrenaline on prostate smooth muscle cells. Previous studies showed that 
α1-blockers increased the Qmax by around 20-25% and reduced International 
Prostate Symptom Score (IPSS) by around 30-40% (Djavan et al., 2004b; Kang 
et al., 2011; Manjunatha et al., 2016; Michel et al., 1998; Seo and Kim, 2012). 
α1-blockers can reduce both voiding and storage symptoms, and the efficacy 
seems to be more remarkable in those patients with prostates less than 40 mL 
(Roehrborn et al., 2008b; Roehrborn et al., 2010). α1-blockers take only a few 
weeks to fully develop the efficacy and show well tolerability and safety during 
the treatment (Michel et al., 1998). 
 
5α-reductase inhibitors (5-ARIs) 
Testosterone is converted to dihydrotestosterone (DHT) mediated by the 
enzyme 5α-reductase and thereby has its effects on the prostate, to cause 
prostate hyperplasia and LUTS (Andriole et al., 2004). 5-ARIs inhibit the 
activation of 5α-reductase and induce apoptosis of prostate epithelial cells 
(Rittmaster et al., 1996). The current 5-ARIs available for clinical use are 
finasteride, dutasteride and epristeride. Prostate size was observed to be 
reduced by approximately 18-28% by these compounds, and levels of 
circulating prostate-specific antigen (PSA) were decreased by approximately 
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50% after six to twelve months of treatment with 5-ARIs (Vaughan, 2003). 
These effects could be more remarkable after long-term treatment (Naslund and 
Miner, 2007). 5-ARIs improve IPSS by around 15-30% and increase Qmax by 
around 1.5-2.0 mL/s after two to four years of treatment for those patients with 
LUTS due to BPH (Kirby et al., 2003; McConnell et al., 1998; Roehrborn et al., 
2002). Also, 5-ARIs reduce either the risk of AUR or the need for surgery 
(Roehrborn, 2008). 
 
Muscarinic receptor antagonists 
Muscarinic receptors locate on bladder smooth muscle cells. They are activated 
by acetylcholine, causing contraction of the detrusor. Consequently, muscarinic 
receptor antagonists are used to reduce detrusor smooth muscle contraction in 
order to treat OAB due to DO (Hennenberg et al., 2014a; Hennenberg et al., 
2017b). The current muscarinic receptor antagonists licensed for clinical use 
are tolterodine, solifenacin, propiverine, oxybutynin, fesoterodine, and 
darifenacin. Antimuscarinics can significant reduce urgency episodes, urgency 
incontinence, frequency of micturition and nocturia in patients with OAB 
(Herschorn et al., 2010; Kaplan et al., 2010; Roehrborn et al., 2006; Yokoyama 
et al., 2009). More benefit was observed in men with smaller prostates (PSA 
levels <1.3 ng/mL) from receiving antimuscarinics (Roehrborn et al., 2008a). 
 
Antimuscarinics might decrease the strength of bladder detrusor, and increase 
the post-void residual (PVR) urine in men with mild to moderate BOO 
(Abrams et al., 2006). Also, the increased risk of UR after treatment of 
antimuscarinics should be considered from the theoretical view. 
 
Putative novel muscarinic receptor antagonists have been explored in 
preclinical studies. Izalpinin which was exracted from Alpinia oxyphylla, 
showed an inhibitory effect in muscarinic detrusor contraction in vitro (Yuan et 
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al., 2014). Mokry et al. reported that propantheline significantly decreased the 
acetylcholine-induced smooth muscle contraction of guinea pigs urinary and 
bladder, while the inhibiting effects revealed a little less effective compared 
with oxybutynin (Mokry et al., 2005). 
 
Phosphodiesterase (PDE) inhibitors 
PDE inhibitors (PEDIs) can reduce the smooth muscle tone in the urethra, 
prostate, and detrusor via increasing intracellular cyclic guanosine 
monophosphate (cGMP). The current PDEI licensed for treatment of LUTS is 
tadalafil. Efficacy of PDE5Is could be observed one week following initiation 
of treatment with a reduction of IPSS by 22-37% (Oelke et al., 2012b), and 
after four weeks of treatment with the PDE5Is, approximately 79.3% of studied 
men were reported to have clinical meaningful improvement (Oelke et al., 
2015). PDE5Is reduces smooth muscle tone and significant increases Qmax, but 
shows not any effect on increasing the risk of PVR (Porst et al., 2013). 
 
Other PDE isoforms have been also explored. TC-E 5005, a phosphodiesterase 
10-selective inhibitor, was found to inhibit phenylephrine-, U46619-,	
endothelin 1-3-induced, concentration-dependent contractions as well as 
electric field stimulation (EFS)- induced, frequency-dependent contractions of 
prostate strips in vitro (Hennenberg et al., 2016). PDE 4 inhibitors (PDE4Is), 
Ro 20-1724, rolipram, and RP 73401 also exhibited inhibiting effects on the 
tension induced by norepinephrine of isolated prostatic tissue, and the efficacy 
turned out to be stronger than PDE5Is, sildenafil and BAY 13-1197 (Kedia et 
al., 2012). Reversion of smooth muscle tension with various inhibiting effects 
could be observed with the PDE1 inhibitor Vinpocetine, the PDE2 inhhibitor 
EHNA, and PDE4 inhibitor rolipram (Kedia et al., 2009). 
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β3-adrenoceptor agonists (β3-agonists) 
β3-adrenoceptor agonists can induce detrusor relaxation of bladder via 
stimulating the β3-adrenoceptors which are expressed in smooth muscle cells of 
the bladder (Afeli et al., 2013; Alexandre et al., 2016). The current 
β3-adrenoceptor agonist approved for clinical use in adults with OAB is 
mirabegron. β3-adrenoceptor agonists can significant reduce the symptoms of 
OAB, including frequency of micturition and urgency incontinence. Comparing 
with placebo, β3-adrenoceptor agonists showed no remarkable adverse effects 
on voiding urodynamic parameters such as Qmax, bladder contractility index 
and detrusor pressure of maximum flow. Therefore, the risk of increased PVR 
after treatment of β3-adrenoceptor agonists might be little (Nitti et al., 2013; 
Takeda et al., 2003). However, the efficacy and safety of β3-adrenoceptor 
agonists in long-term therapy remain unclear (Hennenberg et al., 2014a; Michel 
and Gravas, 2016).  
 
Some novel selective β3-adrenoceptors have been reported. A recent study 
showed that 138-355 could cause bladder detrusor relaxation in vitro via 
stimulating β3-adrenoceptor (Yamanishi et al., 2006). Another new compound, 
GW427353, was observed to relax detrusor at low concentrations	(<10µM) and 
to suppress spontaneous detrusor contraction at higher concentrations (>50µM) 
(Biers et al., 2006).  
 
Limits of current therapies 
α1-blockers remarkably reduce the IPSS and increase Qmax, with a reduction of 
IPSS by 30-40% and increases of Qmax of 20-25% (Djavan et al., 2004b; 
Hennenberg et al., 2014a). However, considerable effects of placebo were also 
found in the control group, which showed an IPSS improvement by 
approximately 10–34%, and an Qmax increase up to 27% (Hennenberg et al., 
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2014b). α1-blockers show no effect on reducing the prostate volume, preventing 
the occurrence of acute UR or the need for surgery (Roehrborn, 2006). As to 
5-ARIs, it might only be considered in men with moderate to severe LUTS, for 
patients with prostates size < 40 mL, 5-ARIs might not be more efficacious 
than placebo (Boyle et al., 1996). Besides, the onset of efficacy of 5-ARIs is 
quite slow (usually requires three months), and monotherapy is not effective 
enough for patients with moderate-to-severe LUTS after initiation of therapy 
(Naslund and Miner, 2007). 
 
This disappointing efficacy may be responsible for high discontinuation rates, 
which is associated with LUTS treatment by α1-blockers: thus, one year after 
first prescription of α1-blockers, only 35 % of patients still continued 
medication (Cindolo et al., 2015; Lee et al., 2015). Up to 69 % of patients may 
not be satisfied by treatment with α1-blockers, and still 36-45 % are even 
unsatisfied by combination therapy of α1-blockers with 5-ARIs (Fullhase et al., 
2013). Indeed, insufficient efficacy of α1-blockers is a main reason to change to 
another medication (Kim et al., 2014). This reflects low responder rates: in 
30-35 % of patients, improvements in total IPSS by α1-blockers are below 25 % 
(Chapple et al., 2011; Matsukawa et al., 2013). Regarding Qmax, responder rates 
may be even similar under treatment with α1-blockers and placebo (Chapple et 
al., 2011). Finally, low adherence to medical LUTS therapy was identified as an 
independent risk factor for hospitalization for BPH and for surgery (Cindolo et 
al., 2015). Together, this demonstrates, that the efficacy of α1-blockers 
underlies certain limits, despite their widespread application, so that new 
options with higher efficacy are mandatory (Hennenberg et al., 2014b). 
 
PDE5Is were recommended to treat LUTS in recent years, however, their 
tolerability and safety in long-term use (> 1 year) remain unclear, and their 
effects on reducing prostate size and slowing disease progression are still 
needed to be identified. Although combination therapies such as α1-blockers + 
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5-ARIs, or α1-blockers + muscarinic receptor antagonists have been 
recommended, the increase of relevant adverse effects should be also 
considered (Gratzke et al., 2015). 
 
Plant extracts 
Herbal drugs are made of seeds, pollen, roots, bark, or fruits. Up to date, a 
growing number of plant extracts, such as izalpinin and phellodendron 
amurense have been reported to show effects on reducing smooth muscle 
contraction of either bladder (Brandli et al., 2010; Capasso et al., 2004; Fouda 
et al., 2007; Furer et al., 2015; Ito et al., 2009; Kim et al., 2003; Levin et al., 
2002; Onoruvwe et al., 2001) or prostate (Arruzazabala et al., 2006; Brandli et 
al., 2010; Xu and Ventura, 2010) from animals (rat, rabbit, or pig). A possible 
mechanism on modulating Ca2+ release from intracellular stores was 
demonstrated to be responsible for the inhibitory effect of the flavonoid 
galangin (Dambros et al., 2005), however, the precise mechanisms of most 
reported plant extracts are still unclear, and the confirmation of their effects in 
vivo are warranted.  
 
1.5.2 Novel compounds in pathophysiology and experimental 
therapy of LUTS 
Current pharmacological therapies available for LUTS are characterized by 
limited efficacy, and the disappointing effects may cause high discontinuation 
rates of patients. This makes medical treatment of LUTS still be a challenge, 
therefore development of novel pharmacological options is still quite required 
(Chapple et al., 2011; Fullhase et al., 2013; Hennenberg et al., 2014b; Lee et al., 
2015; Matsukawa et al., 2013). In fact, in recent years, a number of novel 
compounds have been found to be possible potential candidate therapy options 
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for LUTS, and some of them are to be further explored for clinical application. 
 
P2X1-purinoceptor antagonists 
Adenosine 5’-triphosphate (ATP) was demonstrated as an excitatory 
cotransmitter with noradrenaline from sympathetic nerves which innervates the 
prostate smooth muscle contraction of guinea-pig (Buljubasich and Ventura, 
2004) and rat (Ventura et al., 2003). 50-fold greater potency of endogenous 
purinoceptor agonist ATP was observed in aged mice than young adult mice, 
and nerve-mediated smooth muscle contraction containing a component 
elicited by P2X1 purinoceptor could only be observed in prostates from aged 
mice, but not from young adult mice (White et al., 2015).  
 
In vitro experiments showed that P2X1-purinoceptor selective antagonists 
prevented augmentation of rat detrusor contractile response induced by 
hypoxia-glucopenia and reoxygenation (Elliott et al., 2013), which means 
P2X1-purinoceptor antagonists might be a possible future therapeutic option 
for increased purinergic-mediated detrusor contractions. 
 
Cannabinoids agonist 
Previous studies have indicated the importance of the endocannabinoid system 
in LUT dysfunction (Pacher et al., 2006). A cannabinoid agonist, WIN 55212-2, 
has been shown to inhibit electric field stimulation-induced contractions of rat 
prostate smooth muscle (Tokanovic et al., 2007). In human prostatic strips, CP 
55940, a cannabinoid receptor 1/cannabinoid receptor 2 agonist, also showed 
inhibiting effects on nerve-induced contractions (Gratzke et al., 2010). Later 
studies also reported that cannabidiol was observed to reduce 
acetylcholine-induced smooth muscle contraction both from rat and human 
prostates (Capasso et al., 2011). Although cannabinoids agonists are now 
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proved to be effective on reducing contractility, the inhibitory effects seemed to 
be only modest (Gratzke et al., 2010; Tokanovic et al., 2007).  
 
Prostaglandin pathway regulators 
There are mounting evidences that inflammation may act as a risk factor for the 
development of BPH and LUTS (Kramer et al., 2007). Prostaglandin (PG) E2 
has been observed to reduce contractile response of rat prostate gland via acting 
at EP2 subtype (Tokanovic et al., 2010). A recent study showed that MF191, an 
antagonist of PGE2 receptor subtype 4 (EP4), has significant effects on 
cyclophosphamide or PGE2-induced overactive bladder in rats (Chuang et al., 
2012). ONO-8539, an antagonist of PGE2 receptor subtype 1 (EP1), showed 
significant efficacy, safety and tolerability for patients with OAB in a phase II 
study (Chapple et al., 2014).  
 
PG-caused LUTS symptoms could be released by other non-PG inhibitors. 
Latest studies have found that fatty acid amide hydrolase (FAAH) inhibitors, 
transient receptor potential melastin 8 ion channel (TRPM8) -selective 
antagonist (DFL23448) and oleoyl ethyl amide (OEtA), exhibited effects on 
increasing micturition intervals, micturition volumes, and bladder capacity in 
rat presented OAB induced by PGE2 (Gandaglia et al., 2014; Mistretta et al., 
2016). However, the use of PGs for LUTS might be limited when considering 
their widespread effects throughout the whole body. 
 
Cyclooxygenase (Oelke et al.), also known as prostaglandin-endoperoxide 
synthase (PTGS), is an enzyme responsible for the formation of PG. Diclofenac 
and NS-398 have been demonstrated to reduce serotonin, noradrenaline, and 
neurokinin A-induced isolated ureter contractions from pig in a concentration- 
dependent manner via inhibiting COX subtype 2 (Mastrangelo et al., 2000). A 
later study reported that indomethacin, a non-selective COX inhibitor, also 
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showed remarkable effect on reducing spontaneous detrusor contraction from 
isolated bladder of pig (Rahnama'i et al., 2013). The antibiotic erythromycin 
showed inhibiting effects on reducing rat detrusor contractile response induced 
by EFS, carbachol, ATP, and potassium via inhibiting the voltage-sensitve 
calcium channels and releasing calcium from intracellular stores (England et al., 
2004). 
 
Protein kinases (PK) 
It has been well established that prostate smooth muscle contraction is linked to 
a number of intracellular signaling pathways under physiologic and 
pathophysiologic conditions, which include several protein kinases and 
GTPases (Hennenberg et al., 2014b). It has been demonstrated that dysfunction 
of Protein kinase C (PKC) is implicated to cause smooth muscle disorders. It 
has been shown that low concentrations of PKC inhibitors, 
bisindolylmaleimide1 (Bim-1) and Ro318220 (both in 50 nM), and a PKC 
activator, phorbol-12,13-dibutyrate (PDBu) (1 µM) reduced the sensitivity of 
detrusor to carbachol and decreased spontaneous contractions (Hypolite et al., 
2015). 
 
RhoA couples to excitatory receptors and activates Rho kinase, which further 
inhibits myosin light chain phosphatase and maintains a contracted state of 
actin filaments (Hennenberg et al., 2006; Somlyo and Somlyo, 2004). The 
RhoA/Rho kinase pathway has been explored using novel compounds which 
are emerging. Y-27632, a specific inhibitor of Rho kinase, attenuated the 
spontaneous and EFS-induced smooth muscle contractions of human ureteral 
strips in dose-dependent manners (Hong et al., 2005). Similar effects were also 
observed in KCl-induced ureter contractions from rabbits with unilateral 
ureteric obstruction (Turna et al., 2007). Y-27632 inhibited carbachol-mediated 
contractile responses in mouse prostate gland in low concentration (10 µM), 
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and inhibited noradrenaline-mediated contractile responses in high 
concentration (10-30 µM) (White et al., 2013). In human detrusor, Y-27632 and 
another Rho kinase inhibitor, HA1100, both inhibited carbachol-induced 
contractions in the concentration of 10 µM (Kirschstein et al., 2014). The 
RhoA/ROCK-mediated Ca2+ sensitization was also reported to involve in the 
human prostate contraction. Contraction of human prostatic stromal cells 
induced by endothelin-1 could be enhanced by over-expressed RhoA, but 
decreased by Y-27632 or fasudil. In human prostate strips, the 
noradrenaline-induced contraction could also be inhibited by Y-27632 or 
fasudil (Takahashi et al., 2007). Finally, Y-27632 also inhibited 
thromboxane-induced contractions of human prostate strips, besides 
α1-adrenergic contractions (Strittmatter et al., 2011). 
  
P21-activated kinase (PAK) acts together with Rac, which involves in a wide 
range of cellular functions such as cytoskeleton organization, smooth muscle 
contraction, and neuronal functions (Wang et al., 2016b). The PAK inhibitors 
FRAX486 (30 µM) and IPA3 (300 µM) have been observed to significantly 
inhibit prostate smooth muscle contraction induced by EFS, but not by 
noradrenaline or phenylephrine (Wang et al., 2016b). Besides, FRAX486 also 
showed inhibiting effects on endothelin-1- and -2-induced contractions (Wang 
et al., 2016b). Reduced growth of prostate stromal cells (WPMY-1 cells) was 
observed by both inhibitors at the same concentrations (Wang et al., 2016b). 
 
Rac is a small monomeric GTPase which is involved in the regulation of 
smooth muscle tone via cytoskeletal organization (Wang et al., 2015). The Rac 
inhibitors NSC23766 (100 µM) and EHT1864 (100 µM) have been found to 
significantly reduce prostate smooth muscle contractile responses induced by 
noradrenaline, phenylephrine and EFS (Wang et al., 2015). Both inhibitors 
revealed effects of cytoskeletal disorganization and impairment in the growth 
of WPMY-1 prostate cells in these concentrations (Wang et al., 2015).  
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Src family kinases (SFKs) are tyrosine kinases involved in various key cellular 
functions such as rearrangement of actin structures via cycling in and out of 
focal adhesions (Min et al., 2012). A recent study showed that two SFK, 
AZM475271 and, reduced prostate smooth muscle contractile responses to 
noradrenaline-, phenylephrine- and EFS in vitro. Stronger inhibiting effect 
could be observed in combination of PP2 and PF573228 (a focal adhesion 
kinase inhibitor) when compared to PP2 alone (Wang et al., 2016a). Reduced 
proliferation in wildtype of WPMY-1 cells after incubation with each inhibitor 
could be observed but not in cells with c-Src-deficiency(Wang et al., 2016a). 
Finally, first evidence for a role of focal adhesions for promoting prostate 
smooth muscle contraction was derived by a study, showing that inhibitors of 
focal adhesion kinases inhibit adrenergic and neurogenic contractions of human 
prostate strips (Kunit et al., 2014). 
 
Other compounds 
A growing number of other types of compounds are also emerging, which show 
varying effects on the contractility of ureter, bladder, or prostate gland in 
various species. A role of TRPA1 agonists in inhibiting electrically induced 
isolate-ureters contractions has been proposed (Weinhold et al., 2017). 
Blebbistain, a myosin II inhibitor, showed significant effect on reducing 
nerve-evoked detrusor overactivity in a rat model (Zhang et al., 2011). 
Considering the large amount of patients suffering from LUTS, the 
development of novel therapy targets aiming to induce smooth muscle 
relaxation  in the prostate and other LUT regions would be quite necessary 
and promising. 
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1.6 Mechanisms of prostate smooth muscle contraction 
It is widely accepted that an increase in the free intracellular calcium level is a 
precondition to active the smooth muscle contractile proteins, while calcium 
sensitization is important for the ability of smooth muscle cells to maintain a 
contractile response in the presence of submaximal intracellular calcium levels 
(Webb, 2003). Agonist receptors in prostate stroma are regarded as the triggers 
the contraction of prostate smooth muscle. The α1-adrenoceptors (α1ARs) 
belong to the G protein-coupled receptor (GPCR) superfamily which occur in 
α1a, α1b, and α1dAR subtypes in prostate stroma; it was demonstrated that the 
function of α1aAR predominates in the prostate smooth muscle (Andersson et 
al., 1997). Agonist such as noradrenaline or phenylephrine binds to α1ARs and 
increases phospholipase C (PLC) activity, which produces two potent second 
messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (Gandaglia et 
al.). IP3 causes release of calcium (Ca2+), while DAG activates PKC (Wang et 
al., 2014). The binding of Ca2+ and calmodulin results in activation of myosin 
light chain (MLC) kinase, which further phosphorylates the light chain of 
myosin to combine with actin and leads to cross-bridge cycling and smooth 
muscle contraction (Dougherty et al., 2014). When the PLC is activated, a 
small GTP-binding protein RhoA is also activated by Rho guanine nucleotide 
exchange factor (RhoGEF). RhoA could increase the activity of Rho kinase that 
leads to inhibition of myosin phosphatase and maintains the phosphorylation of 
light chain of myosin so that to promote the contractile state (Webb, 2003). 
Similarly, PKC promotes contraction also by inhibition of myosin light chain 
phosphatase (Hennenberg et al., 2008). 
 
In addition to adrenoceptors, non-adrenergic mediators such as endothelin-1 
(Hennenberg et al., 2014b) and thromboxane A2 (TXA2) (Strittmatter et al., 
2011) are also demonstrated to promote smooth muscle contraction. 
Contractions by endotheline-1 and TXA2 might be additive, and even exceed 
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α1-adrenergic tone (Hennenberg et al., 2017a). Endothelin-1 is demonstrated to 
cause contraction of smooth muscle in two signaling pathways. After the 
binding of endotheline-1 and its receptor, the PLC/ diacylglycerol (Gandaglia 
et al.) /IP3 signaling pathway is activated. Meanwhile, the mitogen-activated 
protein kinase (MAPK) is also activated, which further phosphorylates the 
caldesmon to promote contractile state (Bouallegue et al., 2007). TXA2 
receptors are detected in prostate smooth muscle cells, contraction of prostate 
smooth muscle induced by TXA2 may involve in Ca2+/ calmodulin- and Rho 
kinase- dependent mechanisms (Strittmatter et al., 2011).  
 
Recently, it has been proposed that effects of α1-blockers stay incomplete due 
to contributions of non-adrenergic mediators, as these mediators may evoke 
contraction of prostate smooth muscle in parallel to α1-adrenoceptors 
(Hennenberg et al., 2013; Hennenberg et al., 2014b). Not surprisingly, but 
importantly, contractions of these non-adrenergic mediators will not be 
inhibited by α1-blockers, so that they may maintain prostate smooth muscle 
tone and urethral obstruction even under therapy with α1-blockers (Hennenberg 
et al., 2016). Consequently, the benefit from α1-blockers may be limited, as 
long as non-adrenergic contractions still promote smooth muscle tone 
alongside to α1-adrenoceptors (Hennenberg et al., 2016). Probably, 
simultaneous actions of different mediators on prostate smooth muscle cells are 
the normal case in vivo. Therefore, it has been postulated, that novel strategies 
for future therapies with higher efficacy than α1-blockers may only be 
successful, if they target adrenergic and non-adrenergic contractions at once 
(Hennenberg et al., 2016). 
 
Several intracellular effectors have been discovered to closely involve the 
contraction of prostate smooth muscle. P21-Activated Kinase (PAK) was 
demonstrated to promote release of noradrenaline from sympathic 
neurotransmission to smooth muscle cells, which thereby activated 
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postsynaptic α1-adrenoceptors to cause smooth muscle contraction. Meanwhile, 
PAK could be also activated by endothelin receptor A/B, and establishes 
intracellular signaling pathway including Ca2+/PKC/Rho kinase to promote the 
contraction of prostate smooth muscle (Wang et al., 2016b). It was recognized 
that small G-proteins play a key role in smooth muscle contraction (Kitazawa 
et al., 1989). Rac belongs to the small G-proteins, three Rac isoforms (Rac1-3) 
were all detected in prostate tissues (Wang et al., 2015). It was reported that 
Rac has a key role in regulating cytoskeletal organization which is responsible 
for contraction (Zhou et al., 2010). Focal adhesion kinase (Nitti et al.) is 
demonstrated to be the principal requirement for the correct assemble of 
adhesome proteins to dense plaques which enables the attachment of 
cytoskeleton to membranes and of membranes to extracellular matrix, finally 
promoting prostate smooth muscle contraction (Hennenberg et al., 2014b; 
Kunit et al., 2014). Besides, FAK may be also involved in phosphorylation of 
Ca2+ channel (Gerthoffer and Gunst, 2001). 
 
Together and regardless of upstream signaling pathways, there are three 
prerequisites, which are indispensable for smooth muscle contraction, 
comprising 1) phosphorylation of myosin light chains, 2) actin organization 
and polymerization to filaments, and 3) attachment of filaments to membranes 
and extracellular matrix by dense plaques (Walther et al., 2012). Actin 
filaments are essential elements of the cytoskeleton, changes in actin 
polymerization and reorganization are responsible for cellular migration and a 
prerequisite for smooth muscle contraction (Gunst and Zhang, 2008; 
Kirschstein et al., 2015). Although the actomyosin system and actin 
polymerization could be activated independently, the development of smooth 
muscle contraction requires activation of both processes (Gunst and Zhang, 
2008). Effectors on cytoskeleton or actin, such as LIM domain kinase (LIMK) 
(Bernard, 2007), ARF6 (Herlemann et al., 2017), and heat shock protein (HSP) 
(Hedges et al., 1999) are the key point in most of the signaling pathways during 
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the contractile process. 
 
1.7 The role of LIMKs  
LIM kinases (LIMKs) are serine/threonine kinases, which occur in two 
isoforms, LIMK1 and LIMK2. LIMKs regulate actin polymerization through 
phosphorylation of the actin depolymerizing factors (ADF)/cofilin, and thereby 
cause filament organization and stress fibre formation (Bernard, 2007). It has 
been demonstrated that LIMKs act as key factors in regulating muscle 
contraction through various signaling pathways which mainly include 
Rho/ROCK/LIMK1/2, cAMP/PKA/LIMK1/2, Rac/PAK/LIMK1/2, and 
Cdc42/MRCK/LIMK2 pathways (Webb, 2003) (Figure 2).  
 
Although LIMK have been reported to act as crucial regulators in cofilin 
phosphorylation and actin polymerization, as far as we can retrieve, studies on 
effects LIMK selective inhibitors or the role of LIMK during smooth muscle 
contraction have not yet been explored in any organ. This might probably 
because specific small molecular inhibitors were not available before, but now, 
as two LIMK inhibitors SR7826 and LIMKi3 are available, this enables us to 
evaluate their effects on contraction of prostate smooth muscle. 
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Figure 2: Assumed roles of LIMK1 and LIMK2 in smooth muscle contraction. LIMKs 
phosphorylate cofilin to phospho-cofilin, the inactive cofilin thereby causes smooth muscle 
contraction by actin polymerization. This process could be induced by several signaling 
pathways, e.g. Rho/ROCK/LIMK1/2, cAMP/PKA/LIMK1/2, Rac/PAK/LIMK1/2, and 
Cdc42/MRCK/LIMK2 pathways. Two LIMK inhibitors SR7826 and LIMKi3, are 
supposed to inhibit LIMK1 and LIMK1/2, respectively. Because actin polymerization is an 
indispensable prerequisite for smooth muscle contraction, a role of LIMK for promoting 
smooth muscle contraction may be assumed – but this has never been shown.  
Abbreviation: LIMKs, LIM domain kinases; Rho, rhodopsin; ROCK, Rho kinase; cAMP, 
Cyclic adenosine monophosphate; PKA, protein kinase A; RAC, ras-related C3 botulinum 
toxin substrate; PAK, p21-activated kinase; Cdc42, cell division cycle 42; MRCK, 
Cdc42-binding kinase. 
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2. Objective of this thesis	 	
In BPH, smooth muscle contraction in the prostate drives urethral obstruction, 
which often results in LUTS. Consequently, inhibition of contraction is an 
important strategy for medical therapy, but available options still show 
insufficient efficacy. Development of future options with higher efficacy 
requires adequate understanding of contractile mechanisms and identification 
of novel targets in the prostate. However, despite the high clinical relevance of 
contractile mechanisms in the prostate, they are still incompletely understood. 
Recently, a possible role of LIMK has been suggested for actin polymerization 
in different cell types. Because actin polymerization is an ultimate prerequisite 
for smooth muscle contraction, a role of LIMK for regulation of smooth muscle 
tone may be assumed. Surprisingly and to the best of my knowledge, this has 
not been examined or reported to date. Therefore, the aim of this thesis was to 
study a possible role of LIMK for prostate smooth muscle contraction. 
 
Specifically, the aim was to address the following questions:  
(1) Are LIMKs expressed in the human prostate? 
(2) Does the LIMK inhibitor SR7826 inhibit α1-adrenoceptor-induced 
contractions of human prostate strips? 
(3) Does the LIMK inhibitor SR7826 inhibit neurogenic contractions of 
human prostate strips? 
(4) Does the LIMK inhibitor SR7826 inhibit non-adrenergic contractions of 
human prostate strips? 
(5) Does the LIMK inhibitor LIMKi3 inhibit α1-adrenoceptor-induced 
contractions of human prostate strips? 
(6) Does the LIMK inhibitor LIMKi3 inhibit neurogenic contractions of 
human prostate strips? 
(7) Does the LIMK inhibitor LIMKi3 inhibit non-adrenergic contractions of 
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human prostate strips? 
(8) Is actin polymerization in prostate stromal cells susceptible to LIMK 
inhibitors?
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3. Materials and methods 
3.1 Reagents and devices 
Table 1. Reagents used in this study. 
Products Manufacturer 
Potassium chloride (KCl) Roth, Germany 
Sodium chloride (NaCl) Roth, Germany 
Calcium chloride dihydrate (CaCl2•2H2O) Roth, Germany 
Magnesium sulfate heptahydrate 
(MgSO4•7H2O) 
Roth, Germany 
Glucose Roth, Germany 
Sodium bicarbonate (NaHCO3) Sigma-Aldrich, USA 
Potassium hydrogen phosphate (KH2PO4) Applichem, Germany 
Noradrenalin Sigma-Aldrich, USA 
Phenylephrine Sigma-Aldrich, USA 
Methoxamine hydrochloride Sigma-Aldrich, USA 
Custodiol Köhler, Germany 
U46619 Tocris, UK 
Endothelin-1  Enzo, USA 
LIMKi3 Tocris, UK 
SR 7826 Tocris, UK 
Dimethyl sulfoxide (DMSO) Roth, Germany 
RPMI 1640 Gibco, USA 
10 % fetal calf serum (FCS) Gibco, USA 
phosphate-buffered saline (PBS) Gibco, USA 
Milk powder Roth, Germany 
Rabbit phospho-LIMK1 (thr508)/ LIMK2 Cell Signaling Technology, USA 
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(thr505) antibody 
Rabbit anti LIMK1 antibody GeneTex, USA 
Rabbit anti cofilin (D59) Cell Signaling Technology, USA 
Mouse anti p-cofilin 1 Santa Cruz Biotechnology, USA 
Mouse monoclonal anti calponin 1/2/3 Santa Cruz Biotechnology, USA 
Mouse monoclonal anti pan-cytokeratin Santa Cruz Biotechnology, USA 
Mouse monoclonal anti β-actin antibody Santa Cruz Biotechnology, USA 
Mouse monoclonal anti PSA antibody Santa Cruz Biotechnology, USA 
Horse anti mouse IgG Vector Laboratories, USA 
Horse anti goat IgG Vector Laboratories, USA 
Rabbit anti LIMK1 antibody GeneTex, USA 
Rabbit anti p-cofilin antibody Cell Signaling Technology, USA 
Rabbit anti cofilin antibody Cell Signaling Technology, USA 
Mouse anti pan-cytokeratin antibody Santa Cruz Biotechnology, USA 
Mouse anti calponin 1/2/3 antibody Santa Cruz Biotechnology, USA 
Cy5-conjugated goat anti rabbit IgG Abcam, UK 
Cy3-conjugated goat anti mouse IgG Millipore, USA 
Fluorescein isothiocyanate- conjugated 
Rabbit anti goat IgG 
Millipore, USA 
4’,6’-diamidino-2-phenylindole-dihydrochl
oride (DAPI) 
Invitrogen, USA 
Phalloidin Sigma-Aldrich, Germany 
MgCl2 Promega, USA  
Revrse Transcription buffer 10× Promega, USA 
dNTP Mix Promega, USA 
Random Primers Promega, USA 
AMV Revrse Transcriptase Promega, USA 
RNase Inhibitor Promega, USA 
RNase Free Water Promega, USA 
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SYBR™ Green Roche,USA 
RT2 qPCR Primer (LIMK1 & LIMK2) QIAGEN, Germany 
RNeasy Micro Kit QIAGEN, Germany 
AllPrep DNA/RNA/Protein Mini Kit QIAGEN, Germany 
BSA Gibco, USA 
5-Ethynyl-deoxyuridine (5-EdU) Thermo Fisher Scientific, USA 
Buffer additive CS219074 Thermo Fisher Scientific, USA 
6-FAM-Azide Thermo Fisher Scientific, USA 
5/6-Sulforhodamine101-PEG3-Azide Thermo Fisher Scientific, USA 
5-TAMRA-PEG3-Azide Thermo Fisher Scientific, USA 
Eterneon-Red 645 Azide Thermo Fisher Scientific, USA 
10X Reaction Buffer Thermo Fisher Scientific, USA 
Triton X-100 Thermo Fisher Scientific, USA 
Mounting solution Thermo Fisher Scientific, USA 
Dithiothreitol (DTT) Sigma-Aldrich, Germany 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, Germany 
Tris base Sigma-Aldrich, Germany 
LB agar Thermo Fisher Scientific, USA 
Tryptone Sigma-Aldrich, Germany 
Yeast extract Sigma-Aldrich, Germany 
GelRed Thermo Fisher Scientific, USA 
Agarose Sigma-Aldrich, Germany 
Film developers  Kodak, USA 
Polyvinylidene-Fluoride (PVDF) Sigma-Aldrich, Germany 
chemiluminescence (ECL) Hyperfilm GE Healthcare, Germany 
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Solutions used in organ bath were listed in Table 2. 
 
Table 2: Composition of solutions used in organ bath. 
 
Solution Component 
Krebs- Henseleit solution 1 (KH1) NaCl 172.4g 
 KCl 8.8g 
 CaCl2•2H2O 9.2g 
 KH2PO4 4.1g 
 MgSO4•7H2O 7.4g 
Krebs- Henseleit solution 2 (KH2) NaHCO3 32.5g 
Solution in Organ bath (Guirgis et al.) Distilled water 1000ml 
 KH-1 43.5ml 
 Glucose 1.62g 
 KH-2 43.5ml 
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Devices used in this study were listed in Table 3. 
 
Table 3: Devices used in this study. 
 
Products Manufacturer 
Tissue Bath System- 720MO DMT (Danish Myotechnology), 
Denmark 
Electrical Stimulation Fields DMT (Danish Myotechnology), 
Denmark 
Lab pump KNF- Neuberger, USA 
Thermostat Memmert, Germany 
American Type Culture Collection ATCC Manassas, USA 
Light Cycler PCR system Roche, Switzerland 
Protran® nitrocellulose membranes Schleicher & Schuell, Germany 
Gel electrophoresis system Bio- rad, Germany 
Superfrost® microscope slides Thermo Fisher, USA 
Laser scanning microscope Leica SP2, Germany 
Lab-Tek chamber slides Thermo Fisher, USA 
Cell culture incubator Thermo Fisher, USA 
Waterbath Thermo Fisher, USA 
 
3.2 Human prostate 
Human prostate tissues were obtained from patients undergoing radical 
prostatectomy for prostate cancer (n= 123). Prostate tissues from those patients 
who previously received transurethral resection of prostate (TURP) or 
brachytherapy were excluded. All prostates were sent to the Department of 
Pathology immediately after prostatectomy and subsequently macroscopically 
examined by an experienced pathologist. Tissues were then taken from areas of 
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the periurethral zone, where no signs of neoplasia, cancer or inflammation were 
macroscopically observed.  
 
The research was carried out according to the Declaration of Helsinki of the 
World Medical Association, and has been approved by the ethics committee of 
Ludwig-Maximillians University, Munich, Germany. Prostate tissues were 
either stored in Custatdiaol® at 4 °C for organ bath studies for a maximum of 
90 min, or at -80 °C after shock frozen in liquid nitrogen for molecular 
research.  
 
3.3 Cell culture 
The cell line WPMY-1 used in this study which were purchased from American 
Type Culture Collection (ATCC Manassas, VA, USA), is an immortalized cell 
line from human prostate stroma without malignant transformation. Cells were 
recovered from liquid nitrogen and cultured in RPMI 1640 (Gibco, Carlsbad, 
CA, USA) supplemented with 10 % fetal calf serum (FCS) (Gibco, Carlsbad, 
CA, USA) and 1% penicillin (Gibco, Carlsbad, CA, USA)/ Streptomycin 
(Gibco, Carlsbad, CA, USA) at 37 °C in a humidified atmosphere with 5% CO2. 
Cells were washed with PBS (pre-warmed to 37°C by water-bath) (Gibco, 
Carlsbad, CA, USA) and then incubated in 1 ml accutase (37 °C) for 5 min. 
After applying 10 ml of complete culture media to block the digestion process, 
cells were recollected by centrifugation (1,200 rpm, 5 min). Cell pellets were 
resuspended with culture media and transferred to flasks. Cells were detached 
after accutase digestion and centrifuged and resuspended in freezing media of 
1ml (FBS with 10% DMSO), then transferred to a cryotube and stored at 
-80 °C for short-term or nitrogen tank for long-term storage. 
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3.3 Real time polymerase chain reaction (RT-PCR) 
3.3.1 RNA isolation and concentration measurement 
l For isolation from prostate tissues, the tissue amount was 30 mg. Tissues 
were homogenized performed with FastPrep®- 24 system with marix A 
(MP Biomedicals, IIIkirch, France). For isolation from prostate cells, the 
amount of cells was 1 x 107. 
l Add Buffer RLT (600 µl) to prostate tissues or cells.  
l Centrifuge the lysate at maximum speed for 3 min, then remove the 
supernatant by pipetting. 
l Add 600 µl 70% ethanol to the lysate and mix completely by pipetting (no 
centrifuge in this procedure). 
l Transfer 700 µl of the sample (including the precipitate) to the RNeasy 
Mini spin column placed in a 2 ml Eppendorf tube. Close the lid and 
centrifuge at maximal speed for 15 sec, and then discard the flow-through. 
l Add 700 µl Buffer RW1 to the RNeasy spin column, centrifuge at maximal 
speed for 15 sec, and then discard the flow-through. 
l Add 500 µl Buffer RPE to the RNeasy spin column, centrifuge at maximal 
speed for 15 sec, and then discard the flow-through.  
l Add 500 µl Buffer RPE to the RNeasy spin column, centrifuge at maximal 
speed for 2 min, and then discard the flow-through.  
l Place the RNeasy spin column in a new RNase- free collection tube (1.5 
ml), add 50 µl RNase- free water to the spin column membrane, centrifuge 
at maximal speed for 1 min, and then collect the flow-through (repeat this 
procedure if necessary). 
l Concentration measurement of RNA was performed with Nanodrop 
spectrophotometer, Nuclease- free water was used for blanking before 
measuring. 
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3.3.2 Reverse Transcription (RT) 
RNA sample was incubated at 70 °C for 10 min, 1 µg of RNA sample was 
reverse transcribed using Reverse Transcription System (Promega, Madison, 
WI, USA) (Table 4). 
 
Table 4: RT-PCR reaction system. 
 
Components Volumes (µl) 
Random hexamer oligodeoxyribonucleotides 0.5 
Ribonuclease inhibitor 0.5 
Reverse-transcriptase (23 U/µl) 0.65 
dNTP mix, 10 mM 2 
10xRT buffer 2 
MgCl2, 25 mM 4 
RNase-free water 10.35 
 
3.3.3 Primer design 
Based on the RefSeq accession numbers, NM_001204426 for LIMK1, 
NM_001031801 for LIMK2 and NM_002046 for Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), primers were provided by Qiagen (Hilden, Germany) 
as ready-to-use mixes. 
 
3.3.4 Real-time polymerase chain reaction (RT-PCR) 
RT-PCR for LIMK1, LIMK2 and GAPDH was performed with a Roche Light 
Cycler (Roche, Basel, Switzerland). PCR reactions were carried out in a 
volume of 25 µl which contained 5 µl LightCycler® FastStart DNA MasterPlus 
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SYBR Green I (Roche, Basel, Switzerland), 1 µl template, 1 µl primer, and 18 
µl water. The settings run on the Light Cycler were used as followed: 
 
Denaturation 95°C 10 min  
Denaturation 95°C 15 sec 
 
Annealing and 3xtension 60°C 60 sec 
Melting curve    
Cooling    
 
∆∆CP crossing points (CP) method was used to express the results (Livak and 
Schmittgen, 2001). ∆CP was defined as the value which number of cycles 
(Abrams et al.) for LIMKs subtracted the Ct values at which the fluroscence 
signal exceeded a defined threshold of GAPDH (∆CP= CtLIMK - CtGAPDH ). 
Values were then calculated as 2-∆CP and normalized to each other. 
 
3.4 Western blotting 
l Samples preparation:  
Fresh prostate tissues were cut into several small strips at the size of 
approximately 6 x 1 x 1 mm3 and separated into two groups (control and 
inhibitor, or control and agonist, solvent was used as control). Tissues were 
placed in 6-well plates which filled with 10 ml custodiol®, and allowed to 
reach an equilibration period after 20 min before adding inhibitors (1µM of 
SR7826 or LIMKi3), agonist (30 µM of phenylephrine or U46619) or 
control (solvent). Plates were then under continuous shanking at 37 °C for 
incubation.  
For the detection of SR7826- or LIMKi3-induced cofilin phosphorylation, 
the incubation duration was 2 h, control groups were incubated with 
45 cycles	
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solvent DMSO in same conditions. For the detection of agonist-induced 
cofilin and LIMK phosphorylation, the incubation durations were 10 min 
or 45 min for phenylephrine, or 1 h for U46619, control groups were 
incubated with solvent (water for phenylephrine, and ethanol for U46619) 
in same conditions. Tissues were then frozen with liquid nitrogen and 
stored at -80°C until needed. 
l Homogenization of the prostate tissues in a buffer containing 10 µM 
phenylmethanesulfonyl fluoride, 10 µg/ml leupeptine hemisulfate, 1 mM 
benzamidine, and 25 mM Tris/HCl using a FastPrep®-24 system with 
matrix A (MP Biomedicals, Illkirch, France).  
l Centrifugation of the homogenates at 20,00g for 4 min, transfer of the 
supernatant to a new Eppendorf Tubes. 
l Assaying the protein concentration in supernatant using the Dc-Assay kit 
(Biorad, Munich, Germany) according to the manual instruction. 
l Boiling the supernatant for 10 min with sodium dodecyl sulfate (SDS) 
sample buffer (Roth, Karlsruhe, Germany). 
l Subjecting the samples (20 µg/lane) to SDS-polyacrylamide gel 
electrophoresis for separation of the proteins. 
l Electroblotting of the proteins on Protran® nitrocellulose membranes 
(Schleicher & Schuell, Dassel, Germany). 
l Blocking the membranes with PBS containing 5 % milk powder (Roth, 
Karlsruhe, Germany) at 4 °C overnight. 
l Incubation of the membranes with rabbit phospho-LIMK1 (thr508)/LIMK2 
(thr505) antibody (#3841) (Cell Signaling Technology, Danvers, MA, 
USA), rabbit anti LIMK1 (GTX10561-50) (GeneTex, Irvine, CA, USA), 
rabbit anti cofilin (D59) (Cell Signaling Technology, Danvers, MA, USA), 
mouse anti p-cofilin 1 (sc-365882), mouse monoclonal anti calponin 1/2/3 
(sc-136987), mouse monoclonal anti pan-cytokeratin (sc-8018), mouse 
monoclonal anti β-actin antibody (sc-47778) (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), or mouse monoclonal anti PSA (sc-7316) at 4 °C 
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overnight. All primary antibodies were diluted in PBS containing 0.1 % 
Tween 20 (PBS-T) and 5 % milk powder. 
l Washing the membranes with PBS-T three times every five minutes. 
l Incubation with the secondary biotinylated horse anti mouse or horse anti 
goat IgG (BA-1000, BA-2000, BA-9500) (Vector Laboratories, Burlingame, 
CA, USA), then application of avidin and biotinylated HRP from the 
“Vectastain ABC kit” (Vector Laboratories, Burlingame, CA, USA), both 
were diluted 1:200 in PBS. Incubation lasted for 1 h at room temperature.  
l Washing the membranes with PBS-T three times every five minutes. 
l Washing the membranes with PBS once. 
l Developing the blots with enhanced chemiluminescence (ECL) using ECL 
Hyperfilm (GE Healthcare, Germany). 
 
3.5 Fluorescence staining 
l Sample preparation: human prostate tissues were embedded in optimal 
cutting temperature (OCT) compound, and snap-frozen in liquid nitrogen 
and stored at -80 °C until needed. 
l Cuting the prostate specimens into sections (8 µm thick) using a cryostat 
and then mounted on Superfrost® microscope slides (Thermo Fisher, 
Waltham, MA, USA). (Slides should be warmed to room temperature 
before staing) 
l Washing the slides with PBS. 
l Post-fixing the sections using methanol at -20 °C and blocked in 1 % 
bovine serum for 30 min. 
l Incubation of the sections with primary antibodies for 1 h at room 
temperature. Primary antibodies were used in different sections according 
to the target proteins detections and listed as followed: rabbit anti LIMK1 
(GTX10561-50) (GeneTex, Irvine, CA, USA), rabbit anti p-cofilin (serine 
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3) (77G2) (Cell Signaling Technology, Danvers, MA, USA), rabbit anti 
cofilin (D59) (Cell Signaling Technology, Danvers, MA, USA), mouse anti 
pan-cytokeratin (sc-8018), or mouse anti calponin 1/2/3 (sc-136987) (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA). Control groups were stained 
without any primary antibody. 
l Washing the sections with PBST for three time every five minutes. 
l Incubation of the sections with biotinylated secondary antibodies for 30 
minutes at room temperature. Secondary antibodies were used in different 
sections according to the target proteins detections and listed as followed: 
Cy5-conjugated goat anti rabbit IgG (ab6564) (Abcam, Cambridge, UK), 
Cy3-conjugated goat anti mouse IgG (AP124C) (Millipore, Billerica, MA, 
USA), and fluorescein isothiocyanate- (FITC-) conjugated rabbit anti goat 
IgG) (AP106F) (Millipore, Billerica, MA, USA). 
l Washing the sections with PBST for three time every two minutes. 
l Counterstaining the Nuclei with 4’, 
6’-diamidino-2-phenylindole-dihydrochloride (DAPI) (Invitrogen, 
Camarillo, CA, USA). 
l Rinsing in PBST for three time every five minutes. 
l Dehydration through 95% ethanol for two min, and then 100% ethanol for 
twice every 3 min. 
l Coverslip with anti-fade mounting medium. 
l Analyzing the fluorescence with separate detectors using a confocal 
fluorescence microscope. 
 
3.6 Prostate tissue tension measurements	
l Krebs–Henseleit solution preparation for organ bath: put 43.5 ml KH1 and 
1.62 g glucose into distilled water of 1000 ml, gas charged constantly with 
carbogen (95 % O2, 5% CO2) for 25 to 30 min, then adding 43.5 ml KH2 
MATERIALS	AND	METHODS	
37	
	
and gas charged for at least 5 min. KH was stored in flask and warmed and 
maintained at 37 °C in a thermostatic container. 
l Pretension: chambers of organ bath were filled with KH solution of 10ml, 
KH solution was maintained at a temperature of 37 °C and carbogen (95 % 
O2, 5% CO2) was constantly charged in the chamber. Prostate strips were 
cut from fresh prostate tissues in the size of approximate 6 × 3 × 3 mm and 
then fixed in the organ bath. All the tissues were stretched to 4.9 mN and 
left to obtain equilibration for 45 min, during this period, spontaneous 
decreases in tone could be usually observed, so tension was readjusted for 
three times before the tone reached a stable resting tension of 4.9 mN. 
l Maximal contraction of prostate strips: 400 µl of 2 M KCl (final 
concentration: 80mM in chamber) was added to each chamber to induce 
the maximal contraction of prostate strip, after that, the chambers were 
washed with KH solution for three times in a total volume of 30 ml. 
l Inhibitors/agonist preparation and incubation: SR7826 and LIMKi3 were 
dissolved in DMSO, 10 µl of 1 mM SR7826, or 10 µl of 1 mM LIMKi3 
was added in chamber as experiment group, and reached the final 
concentration to 1 µM, respectively. 10 µl of DMSO was added in chamber 
as control. Both inhibitors and solvent were applied to prostate strips at 
least 30 min before adding agonists or electrical field stimulus (EFS).  
l Agonist- and EFS- induced contractions: frequencies of EFS in this study 
were set as 2 Hz, 4 Hz, 8 Hz, 16 Hz, and 32 Hz. Agonists and 
concentrations used in this study were listed in table 5-9 as follow: 
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Table 5. Concentrations of noradrenaline in organ bath. 
 
Concentration Volume Final concentration in organ bath  
0.1 mM 10 µl 0.1 µM 
0.1 mM 20 µl 0.3 µM 
1 mM 7 µl 1 µM 
1 mM 20 µl 3 µM 
10 mM 7 µl 10 µM 
10 mM 20 µl 30 µM 
10 mM 70 µl 100 µM 
 
Table 6. Concentrations of phenylephrine in organ bath. 
 
Concentration  Volume Final concentration in organ bath  
0.1 mM 10 µl 0.1 µM 
0.1 mM 20 µl 0.3 µM 
1 mM 7 µl 1 µM 
1 mM 20 µl 3 µM 
10 mM 7 µl 10 µM 
10 mM 20 µl 30 µM 
10 mM 70 µl 100 µM 
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Table 7. Concentrations of methoxamine in organ bath. 
 
Concentration Volume Final concentration in organ bath  
0.1 mM 10 µl 0.1 µM 
0.1 mM 20 µl 0.3 µM 
1 mM 7 µl 1 µM 
1 mM 20 µl 3 µM 
10 mM 7 µl 10 µM 
10 mM 20 µl 30 µM 
10 mM 70 µl 100 µM 
 
Table 8. Concentrations of U46619 in organ bath. 
 
Concentration  Volume Final concentration in organ bath  
0.1 mM 10 µl 0.1 µM 
0.1 mM 20 µl 0.3 µM 
1 mM 7 µl 1 µM 
1 mM 20 µl 3 µM 
10 mM 7 µl 10 µM 
10 mM 20 µl 30 µM 
 
Table 9. Concentrations of endothelin-1 in organ bath. 
 
Concentration  Volume Final concentration in organ bath  
0.4 mM 2.5 µl 0.1 µM 
0.4 mM 5 µl 0.3 µM 
0.4 mM 17.5 µl 1 µM 
0.4 mM 50 µl 3 µM 
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l Agonist- and EFS- induced contractions calculation: KCl- induced prostate 
smooth muscle contraction was set as 100%, agonists- and EFS- induced 
contractions were expressed as % of KCl- induced contractions. 
 
3.7 Phalloidin staining 
l Cells were digested by tryptase, then transferred and plated on Lab-Tek 
chamber slides (Thermo Fisher, Waltham, MA, USA) at 37 °C in a 
humidified atmosphere with 5% CO2 for culture until reaching a degree of 
fusion to 80%. 
l Cells were applied with SR7826 or LIMKi3 in the concentrations of 5 µM 
and 10 µM, respectively for 24 h. Control group was applied with solvent 
DMSO.  
l Washed the cells with PBS (pre-warmed to 37°C by water-bath) for twice.  
l Cells were fixed by 3.7% paraformaldehyde solution at room temperature 
for 5 – 10 min, and washed again PBS (pre-warmed to 37°C by 
water-bath). 
l Cells were stained with 100 µM fluorescein isothiocyanate- (FITC-) 
labeled phalloidin (Sigma-Aldrich, Munich, Germany) at room temperature 
for 40 min. 
l Washed the cells with PBS for three times to remove the unbound 
phallloidin conjugate. 
l Removed residual water in the cells and added antifade mounting medium 
to the labeled cells. 
l Used a laser scanning microscope (Leica SP2, Wetzlar, Germany) to 
analyze the labeled cells. 
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3.8 Viability assay 
l Dispension of 100 µl of cell suspension (20,000 cells/ well) in a 96-well 
plate and incubated in a humidified incubator (5% CO2, 37°C) for 24 h.  
l Application of inhibitors SR7826 or LIMKi3 into wells to reach 
concentrations to 1 µM or 5 µM, respectively. Added solvent DMSO as 
control. 
l Incubation of the cells in the incubator for different length of time: 24 h, 48 
h or 72 h. 
l Adding 10 µl of 
[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-t
etrazolium monosodium salt (WST-8) from Cell Counting Kit-8 (CCK-8) 
to each well of the plate at the end of each time point (24 h, 48 h or 72 h). 
Performed the separate control experiments for each time point. (Avoiding 
introduce bubbles to the wells in this procedure) 
l Incubation of the plate for 2 h in the incubator. 
l Measuring the absorbance at 450 nm performed with a microplate reader. 
 
3.9 Statistical analysis 
Data in this study were presented as means ± standard error of the mean (SEM) 
with the indicated number of each experiment. Both Emax and EC50 values were 
calculated by curve fitting of single experiment using GraphPad Prism 6 
(Statcon, Witzenhausen, Germany). Multivariate analysis of variance (ANOVA) 
and two-way ANOVA were used to calculate paired or unpaired observations 
performed with SPSS® 20.0 (IBM SPSS Statistics. Armonk, New York: IBM 
Corporation.). P values <0.05 were considered to be statistically significant.
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4 Results 
4.1 Detection of LIMK and cofilin in human prostate tissues 
4.1.1 Detection of target proteins by Western blotting 
Prostate tissues from eight patients were subjected to Western blotting for 
detection of LIMK and cofilin. Western blot analysis of prostate tissues using 
an antibody against LIMK1 revealed bands at 72 kDa which hits the expected 
molecular weight of LIMK1. These target bands could be observed in each 
sample included in this study, while the intensity of bands obtained from each 
sample differed (Figure 3). Western blot analysis of prostate tissues using an 
antibody against cofilin 1 revealed bands at 18.5 kDa which hits the expected 
molecular weight of cofilin 1. These target bands could be observed in each 
sample included in this study, and the intensity of bands obtained from each 
sample revealed similar (Figure 3). 
 
Western blot analysis of calponin and pan-cytokeratin were used as markers for 
smooth muscle and epithelial glandular cells in included samples, respectively. 
Bands of calponin and pan-cytokeratin were observed in the molecular weight 
of 34 kDa and 37-55 kDa, respectively, despite various intensity of bands were 
obtained from different samples. PSA was also detected in most of the included 
samples in the expected molecular weight of 29 kDa, and obvious variation in 
bands intensity from different patients were also observed (Figure 3). 
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Figure 3: Detection of LIMK and cofilin in human prostate tissues. Prostate 
tissues for Western blot analysis were from n= 8 patients. Bands of LIMK1 and 
cofilin were observed in the expected molecular weight of 72 kDa and 18.5 kDa 
from all the included samples. Bands of calponin in molecular weight 34 kDa were 
observed and served as a marker for smooth muscle cells. Bands of pan-cytokeratin 
in molecular weight 37-55 kDa were observed and served as a marker for 
endothelial cells (glands). Bands of prostate-specific antigen (PSA) in were in 
molecular weight 29 kDa were observed and served as a marker for different 
degrees of benign prostate hyperplasia.  
 
4.1.2 Detection of target proteins by fluorescence staining 
Fluorescence stainings of prostate sections were performed using anti-LIMK1, 
anti-calponin, anti-phospho-calponin, calponin, or pan-cytokeratin antibodies. 
As shown in Figure 4A, with antibodies against LIMK1, calponin and 
pan-cytokeratin, colocalization with immunoreactivity for calponin and 
pan-cytokeratin indicated that LIMK1 located in smooth muscle (Figure 4A), 
and limitedly extent to glandular epithelium (Figure 4A). 
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With an antibody raised against cofilin 1, colocalization with immunoreactivity 
suggested that cofilin 1 located in the stroma (Figure 4B), and to lesser extent 
in the glandular epithelium (Figure 4B2). Also, colocalization with 
immunoreactivity for calponin indicated localization of the cofilin 
immunoreactivity in smooth muscle cells (Figure 4B). With an antibody raised 
against phospho-calponin, colocalization with immunoreactivity suggested that 
phospho-calponin located in the stroma (Figure 4A1), and to lesser extent in 
the glandular epithelium (Figure 4C2). 
 
A1 
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Figure 4: Immunofluorescence staining of human prostate tissues. 
Sections were double labelled with antibodies for LIMK1 (A), cofilin (B), 
or phospho-cofilin (p-cofilin) (C), together with antibodies for calponin 
(marker for smooth muscle cells) or pan-cytokeratin (marker for glandular 
epithelial cells). Yellow color in merged pictures indicates colocalization of 
targets. Shown are representative stainings from series with tissues from 
n=5 patients for each combination. 
 
4.1.3 Detection of LIMK mRNA by RT-PCR in prostate 
tissue and WPMY-1 cells 
Expression levels of LIMK1 and LIMK2 in prostate tissue and WPMY-1 cells 
were detected by RT-PCR. Prostate tissues were from seven patients, and cells 
from four independent experiments. Expression levels of LIMK1 and LIMK2 
in each prostate sample revealed different. Remarkable higher expression levels 
of both LIMK1 and LIMK2 were detected in prostate tissue comparing to 
WPMY-1 cells (Figure 5). 
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Figure 5: Detection of LIMK in human prostate tissues and WPMY-1 cells. 
Samples of prostate tissues and WPMY-1 cells were subjected to RT-PCR (tissues 
from n=7 patients, and cells from n=4 independent experiments).	Data were ΔΔCP 
values (2^-(Cttarget-CtGAPDH), normalized to each other) and median values (bar). 
 
4.2 Effects of SR7826 and LIMKi3 on 
noradrenaline-induced contractions 
Noradrenaline (0.1- 100 µM) induced concentration-dependent contractions of 
prostate strips, which were inhibited by SR7826 (1 µM) and LIMKi3 (1 µM). 
Multivariate analysis showed that inhibiting effects of SR7826 were significant 
at 30 µM (p=0.046) and 100 µM (p=0.045) noradrenaline, and that inhibiting 
effects of LIMKi3 were significant at 30 µM (p=0.029) noradrenaline (Figure 
6). Comparisons between inhibitor and control groups conducted by two-way 
ANOVA indicated significant inhibition of noradrenaline-induced contractions 
by SR7826 (p=0.006) and LIMKi3 (p=0.002). 
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Figure 6: Effects of SR7826 and LIMKi3 on noradrenaline-induced 
contractions of human prostate strips. Contractions of human prostate strips 
were induced by noradrenaline in cumulative concentrations in an organ bath. 
Effects of SR7826 or LIMKi3 on contractions were compared with DMSO 
(control) in separate sets of experiments. To eliminate heterogeneities due to 
different degrees of BPH and smooth muscle contents, tensions were expressed 
as % of contraction induced by 80 mM KCl, which was assessed before 
application of inhibitors and solvent. Data are shown as means ± SEM from series 
with tissues from n=13 for SR7826, and n=9 for LMKi3, in which samples from 
every patient were assigned in both inhibitor and control groups (* P< 0.05 for 
control vs. inhibitor). 
 
4.3 Effects of SR7826 and LIMKi3 on 
phenylephrine-induced contractions 
Phenylephrine (0.1- 100µM) induced concentration-dependent contractions of 
prostate strips, which were inhibited by SR7826 (1 µM) and LIMKi3 (1 µM). 
Multivariate analysis showed that inhibiting effects of SR7826 were significant 
at 10 µM (p=0.017), 30 µM (p=0.014) and 100 µM (p=0.015) phenylephrine, 
and that the inhibiting effects of LIMKi3 were significant at 10 µM (p=0.004) 
and 30 µM (p=0.016) phenylephrine (Figure 7). Comparisons between inhibitor 
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and control groups conducted by two-way ANOVA indicated significant 
inhibition of phenylephrine-induced contractions by SR7826 (p<<0.001) and 
LIMKi3 (p< <0.001).  
 
  
Figure 7: Effects of SR7826 and LIMKi3 on phenylephrine-induced 
contractions of human prostate strips. Contractions of human prostate strips 
were induced by phenylephrine in cumulative concentrations in an organ bath. 
Effects of SR7826 or LIMKi3 on contractions were compared with DMSO 
(control) in separate sets of experiments. To eliminate heterogeneities due to 
different degrees of BPH and smooth muscle contents, tensions were expressed 
as % of contraction induced by 80 mM KCl, which was assessed before application 
of inhibitors and solvent. Data were showed as means ± SEM from series with 
tissues from n=9 for SR7826, and n=5 for LMKi3, in which samples from every 
patient were assigned in both inhibitor and control groups (* P< 0.05 for control vs. 
inhibitor). 
 
4.4 Effects of SR7826 and LIMKi3 on methoxamine-induced 
contractions 
Methoxamine (0.1- 100µM) induced concentration-dependent contractions of 
prostate strips, which were inhibited by SR7826 (1 µM) and LIMKi3 (1 µM). 
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Multivariate analysis showed that inhibiting effects of SR7826 were significant 
at 30 µM (p=0.018) and 100 µM (p=0.021) methoxamine, and that the 
inhibiting effects of LIMKi3 were significant at 10 µM (p=0.006), 30 µM 
(p=0.012) and 100 µM (p=0.032) methoxamine (Figure 8). Comparisons 
between inhibitor and control groups conducted by two-way ANOVA indicated 
significant inhibition of methoxamine-induced contractions by SR7826 
(p=0.008) and LIMKi3 (p=0.001).  
 
  
Figure 8: Effects of SR7826 and LIMKi3 on methoxamine- induced 
contractions of human prostate strips. Contractions of human prostate strips 
were induced by methoxamine in cumulative concentrations in an organ bath. 
Effects of SR7826 or LIMKi3 on contractions were compared with DMSO 
(control) in separate sets of experiments. To eliminate heterogeneities due to 
different degrees of BPH and smooth muscle contents, tensions were expressed 
as % of contraction induced by 80 mM KCl, which was assessed before application 
of inhibitors and solvent. Data were showed as means ± SEM from series with 
tissues from n=6 for SR7826, and n=5 for LMKi3, in which samples from every 
patient were assigned in both inhibitor and control groups (* P< 0.05 for control 
vs. inhibitor). 
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4.5 Effects of SR7826 and LIMKi3 on endothelin-1-induced 
contractions  
Endothelin-1 (0.1- 3 µM) induced concentration-dependent contractions of 
prostate strips. Two preliminary series (n=3 prostates/group for both SR7826 
and LIMKi3) did not indicate the possibilities that SR7826 and LIMKi3 may 
have inhibiting effects on endothelin-1-induced contractions (Figure 9), so that 
these exploratory series were halted after three cases.  
 
  
Figure 9: Effects of SR7826 and LIMKi3 on endothelin-1- induced 
contractions of human prostate strips. Contractions of human prostate strips 
were induced by endothelin-1 in cumulative concentrations in an organ bath. 
Effects of SR7826 or LIMKi3 on inhibiting contractions were compared with 
DMSO (control) in separate sets of experiments. To eliminate heterogeneities due 
to different degrees of BPH and smooth muscle contents, tensions were expressed 
as % of contraction induced by 80 mM KCl, which was assessed before application 
of inhibitors and solvent. Data were showed as means ± SEM from series with 
tissues from n=3 for both SR7826 and LMKi3, in which samples from every 
patient were assigned in both inhibitor and control groups. 
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4.6 Effects of SR7826 and LIMKi3 on U46619-induced 
contractions 
U46619 (0.1- 30µM) induced concentration-dependent contractions of prostate 
strips, which were inhibited by SR7826 (1 µM) and LIMKi3 (1 µM). 
Multivariate analysis showed that inhibiting effects of SR7826 were significant 
at 1 µM (p=0.041), 3 µM (p=0.028) and 10 µM (p=0.024) U46619, and that the 
inhibiting effects of LIMKi3 were significant at 1 µM (p=0.04), 3µM 
(p=0.021), 10 µM (p=0.007) and 30 µM (p=0.011) U46619 (Figure 10). 
Comparisons between inhibitor and control groups conducted by two-way 
ANOVA indicated significant inhibition of U46619-induced contractions by 
SR7826 (P<0.001) and LIMKi3 (P<0.001). 
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Figure 10: Effects of SR7826 and LIMKi3 on U46619- induced contractions of 
human prostate strips. Contractions of human prostate strips were induced by 
U46619 in cumulative concentrations in an organ bath. Effects of SR7826 or 
LIMKi3 on contractions were compared with DMSO (control) in separate sets of 
experiments. To eliminate heterogeneities due to different degrees of BPH and 
smooth muscle contents, tensions were expressed as % of contraction induced by 
80 mM KCl, which was assessed before application of inhibitors and solvent. Data 
were showed as means ± SEM from series with tissues from n=5 for both SR7826 
and LMKi3, in which samples from every patient were assigned in both inhibitor 
and control groups (* P< 0.05 for control vs. inhibitor). 
 
4.7 Effect of SR7826 and LIMKi3 on EFS-induced 
contractions	
EFS (2-32 Hz) induced frequency-dependent contractions of prostate strips, 
which were inhibited by SR7826 (1 µM) and LIMKi3 (1 µM). Multivariate 
analysis showed that inhibiting effects of both SR7826 and LIMKi3 were 
significant at 16 Hz (p=0.013 for SR7826, p=0.04 for LIMKi3) and 32 Hz 
(p=0.002 for SR7826, p=0.008 for LIMKi3) (Figure 11). Comparisons between 
inhibitor and control groups conducted by two-way ANOVA indicated 
significant inhibition of EFS-induced contractions by SR7826 (p=0.002) and 
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LIMKi3 (p=0.018). 
 
  
Figure 11: Effects of SR7826 and LIMKi3 on EFS- induced contractions of 
human prostate strips. Contractions of human prostate strips were induced by 
EFS in different frequencies in an organ bath. Effects of SR7826 or LIMKi3 on  
contractions were compared with DMSO (control) in separate sets of experiments. 
To eliminate heterogeneities due to different degrees of BPH and smooth muscle 
contents, tensions were expressed as % of contraction induced by 80 mM KCl, 
which was assessed before application of inhibitors and solvent. Data were showed 
as means ± SEM from series with tissues from n=5 for both SR7826 and LMKi3, 
in which samples from every patient were assigned in both inhibitor and control 
groups (* P< 0.05 for control vs. inhibitor). 
 
 
4.8 Effect of SR7826 and LIMKi3 on cofilin phosphorylation 
Prostate tissues were incubated with either SR7826 or LIMKi3 (both 1 µM) for 
0.5 h. Subsequently, serine-3-phosphorylated cofilin was detected by Western 
blotting using a site- and phospho-specific antibody. As shown in Figure 12, the 
content of phospho-cofilin in prostate tissues was reduced by SR7826 and 
LIMKi3. SR7826 reduced the phospho-cofilin content by 59 ±15 % compared 
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with control, while LIMKi3 reduced the content of phospho-cofilin by 56 
±13 %. These two inhibitors seemed to have no effect on total cofilin which 
revealed unchanged contents after incubation, also, the content of β-actin 
remained unchanged. 
 
 
Figure 12: Effects of SR7826 and LIMKi3 on cofilin phosphorylation in 
human prostate tissues. Prostate tissues were incubated with SR7826 (1 µM) or 
DMSO (control) (A), or with LIMKi3 (1 µM) or DMSO (control) (B) in separate 
series of experiments. The phosphorylation state of cofilin was then 
semiquantitatively compared between both inhibitor and control groups performed 
with Western blotting using a site- and phospho-specific cofilin antibody. Value for 
each sample was normalized to the mean of each corresponding control group. Data 
were shown as representative blots, and means ± SEM from series with tissues from 
patients n=7 (SR7826) or n=6 patients (LIMKi3). 
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4.9 Effect of phenylephrine and U46619 on LIMK and 
cofilin phosphorylation 
 
Prostate tissues were incubated with different contractile agonists, and contents 
of phospho-LIMK, LIMK, phospho-cofilin, cofilin, and β-actin were then 
assessed by Western blotting. As shown in Figure 13, after incubation with 
phenylephrine (30 µM) for 10 (Figure 13A) or 45 min (Figure 13B), or with 
U46619 (30 µM) for 1 h (Figure 13C), the content of phospho-LIMK, LIMK, 
phospho-cofilin, cofilin, or β-actin in prostate tissues remained unchanged. 
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Figure 13: Effects of phenylephrine and U46619 on LIMK and cofilin 
phosphorylation in human prostate tissues. In each experiment, prostate tissues 
were incubated with phenylephrine (“PE”) (100 µM) for 10 min (A), or 45 min (B), 
or with U46619 (30 µM) for 1 h (C), or with solvent (water for PE, ethanol for 
U46619). Subsequently, Western blot analyses performed with site- and 
phospho-specific antibodies were used for semiquantitative comparison of the 
phosphorylation states of LIMK and cofilin between agonist and control groups. The 
values of total LIMK and cofilin in each sample were also detected to normalize to 
the mean of the corresponding control group (samples without treating with 
agonists). Data were presented as means ± SEM from series with tissues from 
patients n=5 (PE for 10 min), n=3 (PE for 45 min), or n=7 (U46619 for 1 h). 
 
4.10 Effect of SR7826 and LIMKi3 on viability of WPMY-1 
cells 
Both inhibitors, SR7826 and LIMKi3, showed a concentration-dependent effect 
on viability of WPMY-1 cells. At the concentration of 1 µM (which 
significantly inhibited smooth muscle contraction of prostate stripes) of 
SR7826 and LIMKi3, only minor reduced viabilities were observed after 
exposure to inhibitors for 24h (control vs. SR7826 and LIMKi3= 1.197: 1.133 
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and 1.103), 48h (1.246: 1.127 and 1.049) or 72h (1.357: 1.193 and	 1.082) 
(Figure 14). At the concentration of 5 µM, both inhibitors showed markedly 
reduced effects on cells viability after 24h (control vs. SR7826 and LIMKi3= 
1.197: 1.027 and 0.951), 48h (1.246: 1.004 and 0.8264), or 72h (1.357: 1.054 
and	 0.770) of exposure. Minor altered viabilities of cells in each separated 
period (24, 48, or 72h) were observed after exposure to the same concentration 
(1 µM or 5 µM) of SR7826 or LIMKi3, which failed to show a time-dependent 
effect on viability of WPMY-1 cells. 
 
 
Figure 14: Concentration-dependent effects of SR7826 and LIMKi3 on WPMY-1 
cells. WPMY-1 cells were exposed to SR7826 or LIMKi3 in concentrations of 1 µM 
or 5 µM for 24, 48, or 72h, respectively. Cells without inhibitors under the same 
conditions were treated as controls. Data were shown as means ± standard deviation 
(SD) from n=5 independent experiments. 
 
4.11 Effects of SR7826 and LIMKi3 on actin organization of 
WPMY-1 cells 
Polymerized actin in WPMY-1 cells was visualized by phalloidin staining. In 
control groups, where cells were treated with solvent DMSO, actin was 
observed to be organized to thin and long filaments, and filamentous 
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protrusions of different cells overlapped each other (Figure 15). Exposure to 
SR7826 or LIMKi3 for 24 h revealed concentration-dependent effects on actin 
filaments. After exposure with 5 µM SR7826, filaments length was reduced in 
some cells. Cells which were still visible revealed similar actin organization to 
cells in controls, but these were of lesser amount (Figure 15A). Extensive 
breakdown of actin organization was observed after exposure with 10 µM 
SR7826, so that phalloidin-stained actin was invisible in most cells and only 
very short filaments remained in very few cells (Figure 15B). The 
concentrations of 5 and 10 µM of LIMKi3 showed similar, 
concentration-dependent effects on extensive breakdown of actin organization: 
actin filaments partly disappeared after exposure to 5 µM of LIMKi3 after 24 h, 
and after exposure to 10 µM of LIMKi3 for 24 h, remaing phalloidin-stained 
actin was found to be shorter, and completely restricted to the rim of some 
nuclei (Figure 15B). 
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A Control SR7826 (24 h) 
5 µM 
SR7826 (24 h) 
10 µM 
   
B Control LIMi3 (24 h) 
5 µM 
LIMi3 (24 h) 
10 µM 
   
Figure 15: Effects of SR7826 and LIMKi3 on WPMY-1 cells. WPMY-1 cells were 
exposed to SR7826 or LIMKi3 in concentrations of 5 µM or 10 µM for 24 h. WPMY-1 
cells treated with slovent DMSO under the same conditions were set as controls. Both 
SR7826 (A) and LIMKi3 (B) showed concentration-dependent effects on actin 
organization of WPMY-1 cells. Shown are representative pictures from n=3 
independent experiments in both (A) and (B). 
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5 Discussion  
The findings in this thesis suggest that LIMK inhibitors may inhibit prostate 
smooth muscle contraction in vitro. To the best of my knowledge, this is the 
first study to explore the effects of small molecule LIMK inhibitors on 
regulation of smooth muscle contraction in the prostate or even in any organ. 
 
Prostate tissues used in this study were obtained from patients undergoing 
radical prostatectomy due to prostate cancer. All the samples were taken from 
periurethral zone, while most prostate tumors are located to the peripheral zone 
(Pradidarcheep et al., 2011; Shaikhibrahim et al., 2012). Samples were 
characterized by high variations in the content of PSA which could be detected 
by Western blotting (Figure 3). As PSA increases with degree of hyperplasia, 
this may suggest different grades of BPH in the investigated samples (Levitt 
and Slawin, 2007). Actually, around 80% or more patients undergoing 
prostatectomy accompany with BPH with different degrees (Alcaraz et al., 
2009; Orsted and Bojesen, 2013). So the samples used in this study may be 
considered as hyperplastic, but not malignant. Prostate tissues from patients 
undergoing TURP may show more pronounced hyperplasia. However, tissues 
may be seriously traumatized or denaturation after being resected from the 
prostate, and the size of any available samples may be lower than that obtained 
from radical prostatectomy. Anyway, in most patients undergoing TURP, the 
periurethral zone will be mostly ablated, so that samples from this zone are not 
accessible any more. For these reasons, prostate tissues were obtained from 
patients underwent prostatectomy instead TURP.  
 
Different content of calponin between investigated samples was detected by 
Western blotting. This reflects a diverging content of smooth muscle between 
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the samples from different prostates. Different content of pan-cytokeratin 
between investigated samples was also observed, probably due to divergent 
stromal/glandular ratio in samples, which may reflect the individual variation 
of tissue composition of prostates (Figure 3). Immunofluorescence staining of 
pan-cytokeratin and calponin showed typical architecture composed of stroma 
and glands but also with variation between each invested sample (Figure 4). 
Notably, the positive detection of pan-cytokeratin and calponin may thereby 
confirm that the investigated samples in this project contain normal glandular 
and prostate smooth muscle, which could guarantee the quality of studied 
samples. To correct the heterogeneity between samples, all contractions in 
organ bath experiments were referred to receptor- independent tensions induced 
by 2 M KCl. 
 
LIMK1 and LIMK2 are encoded by separate genes which locate on 
chromosomes 7q11.23 and 22q12.2, respectively. Widespread distribution of 
LIMK1 and LIMK2 has been reported in previous studies. LIMK1 was found 
to be widely expressed in embryonic as well as tissues from mouse and human, 
with remarkably high expression in tissues from brain, lung, stomach, kidney 
and testis (Foletta et al., 2004). Compared to LIMK1, LIMK2 was also found 
in most of examined tissues, while with the exceptions of kidney glomeruli, 
testis and glial cells (Acevedo et al., 2006). In the present study, expressions of 
LIMK1 and LIMK2 in prostate tissues as well as WPMY-1 cells were 
confirmed performed with RT-PCR, western blotting and immunofluorescence 
(Figure 3 and 4). 
 
Previous studies on LIMK in the prostate mainly focused on oncologic 
investigations. Overexpressed levels of LIMK1 in prostate adenocarcinomatous 
tissues and malignant prostate cell lines were observed, and it might be 
assumed that LIMK were essential for the invasive property and the growth of 
prostate cancer cells (Davila et al., 2003). In contrast, suppression of upstream 
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regulators in the LIMK-associated signaling pathways caused downregulation 
of LIMK, which thereby inhibited proliferation of prostate cancer in vitro (Cai 
et al., 2015; Zhu et al., 2015). Also, downregulation of LIMK inhibited by 
LIMK selective inhibitors has been demonstrated to reduce motility and 
proliferation of prostate cancer cells (Mardilovich et al., 2015).  
 
LIMK are homologous serine/threonine kinases which may be activated by 
Rho/ROCK, cAMP/PKA, Rac/PAK, and Cdc42/MRCK signaling pathways 
(Bernard, 2007). LIMK phosphorylate cofilin proteins on serine 3 and thereby 
act as regulators of actin-myosin cytoskeletal dynamics, which includes actin 
polymerization, filament assemble, and stress fiber formation in a number of 
various cell types. (Hennenberg et al., 2008; Hennenberg et al., 2014b, a; San 
Martin et al., 2008; Scott and Olson, 2007). Previous studies on relation 
between LIMK and smooth muscle cells or tissues were quite few, and most of 
them were mainly focusing on inhibiting the upstream modulator of 
LIMK-associated signaling pathways which caused change in LIMK 
expression, but not directly upregulating or downregulating the expression of 
LIMK itself. Thus, direct evidence from functional studies for an involvement 
of LIMK in smooth muscle contraction, e. g. from application of small 
molecule inhibitors in organ bath studies is still absent. After treating with 
ROCKII inhibitor, attenuated phosphorylated LIMK1/2 and phosphorylated 
cofilin were observed in vascular smooth muscle cells, which thereby reduced 
the vascular structural remodeling (Al-Ghabkari et al., 2016). Force-induced 
RhoA activation was also reported to promote phosphorylation of LIMK and 
cofilin, and hence increased hypertrophic growth of the myocardium (Zhao et 
al., 2007). Platelet derived growth factor (PDGF) and IL-	1ß, were reported to 
promote proliferation and migration of smooth muscle cells and cause 
pulmonary hypertension via upregulating of phosphorylation of LIMK and 
cofilin (Bongalon et al., 2004; Wilson et al., 2015). 
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SR7826 and LIMKi3 are small molecule inhibitors, which inhibit LIMK1 
(SR7826 and LIMKi3) and LIMK2 (LIMKi3) with high potency. In biochemical 
kinase assays, where inhibition was assessed using recombinant kinases in vitro, 
SR7826 inhibited LIMK1 with an IC50 value of 43 nM, while LIMKi3 inhibited 
LIMK1- and -2 with IC50 values of 7-8 nM (Ross-Macdonald et al., 2008; Yin et 
al., 2015). As to SR7826, comparing to the concentration used in this study (1 
µM), its IC50 values for other kinases ranged much higher, for example, more 
than 5 µM for ROCK1 and ROCK2. It is widely accepted that, due to the 
different access to the inhibitors’ targets resulting from barriers like connective 
tissue or membranes, IC50 values in biochemical assays are usually lower than 
EC50 values in organ bath experiments and in intact tissues (Hennenberg et al., 
2016; Swinney, 2004; Vauquelin et al., 2002). So it may be reasonable that the 
concentration of 1 µM used for SR7826 and LIMKi3 in this study was 
comparably low, and still below IC50 values for non-specific kinase inhibition 
indicated in biochemical assays. Inhibition of LIMK2 by SR7826 has not been 
reported, so that it may be assumed that the inhibition of prostate contraction 
occurred by inhibition of LIMK1 rather than LIMK2. However, it is presently 
not possible to estimate whether inhibition of LIMK2 by SR7826 is in fact 
lacking, or whether this reflects lack of data. 
 
LIMK can be phosphorylated at threonine 508 by upstream signaling pathways 
(e.g. ROCK isoforms), and thereby affect its substrate cofilin (Bernard, 2007). 
As observed in this study, the content of phospho-cofilin in prostate tissues was 
significantly reduced after being treated with SR7832 and LIMKi3, while the 
content of phospho-LIMK remain unchanged in these tissues. This may allow 
the conclusion that inhibition of prostate smooth muscle contraction was 
mainly caused by specific inhibitions of LIMK1 and/or LIMK2, but did not 
involve inhibition of ROCK isoforms. In fact, Rho kinases are activated by 
contractile receptors, so that LIMK would be observed here, if LIMK 
activation involved Rho kinase (Hennenberg et al., 2006). Moreover, it may be 
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concluded that threonine 508 is no substrate for LIMK autophosphorylation in the 
prostate, as no decreases in LIMK phosphorylation at this position were induced by 
SR7826 or LIMKi3. 
 
In prostate tissues, inhibition of cofilin phosphorylation was limited to 56-59 %, what 
may be attributed to LIMK inhibition. As a certain degree of remaining 
phosphorylated cofilin was observed in the presence of LIMK inhibitors, a 
contribution of additional kinases to cofilin phosphorylation in prostate tissues and 
WPMY-1 cells appears possible. 
 
In the organ bath experiments, we observed that small molecule LIMK 
inhibitors inhibited contractile responses induced by α1-adrenergic receptor 
agonist which induced noradrenaline, phenylephrine, and methoxamine. The 
inhibitions ranged around 30%, which may be a little weaker than the 
inhibiting effect of tamsulosin, the approved clinical used α1-adrenergic blocker 
(Gratzke et al., 2015; Hennenberg et al., 2017a; Oelke et al., 2013). While in 
the EFS-induced muscle contractions, which are assumed to be mediated by 
release of endogenous neurotransmitters, and further activation of postsynaptic 
α1-adrenoceptors on smooth muscle cells, these two inhibitors showed 
inhibitions ranged around 50% that may equal or even exceed the inhibiting 
effect of α1-adrenergic blocker (Buono et al., 2014; Oger et al., 2010). 
 
Strikingly, SR7826 and LIMKi3 were also observed to inhibit agonist-induced 
contractions caused by the thromboxane A2 analog U46619. It may be 
hypothesized that these two inhibitors could improve urodynamic parameters in 
vivo, which may resemble, or even exceed the effects of clinical approved used 
α1-blockers. SR7826 and LIMKi3 failed to show inhibiting effects on 
endothelin-1-induced smooth muscle contraction after three independent 
experiments, so that organ bath series with endothelin-1 were discontinued for 
economic reasons after three experiments, because it was obvious that 
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inhibitions were unlikely to be expected. Endothelin-1 is one of the most 
important endogenous smooth muscle constrictors; it can activate DAG and 
Rho and further phosphorylates MLC, but not cofilin, to cause smooth muscle 
contraction (Bouallegue et al., 2007). It might be speculated that the different 
signaling pathways activated by endothelin-1 may contribute to the absence of 
inhibiting effects by SR7826 and LIMKi3. 
 
It has been reported that some smooth muscle contractile agonists, which 
include phenylephrine, noradrenaline, endothelin-1, angiotensin II, thrombin, 
and 5-hydroxytryptamine (5-HT) induce LIMK activation and cofilin 
phosphorylation in vascular smooth muscle cells (Dai et al., 2008; Du et al., 
2010). To identify whether contractile agonists could activate LIMK in prostate, 
their effects on LIMK and cofilin phosphorylation were tested. U46619 is a 
synthetic analog of prostaglandin PGH2 and acts as a thromboxane A2 receptor 
agonist, while phenylephrine is a selective α1-adrenergic receptor agonist. After 
being treated with phenylephrine for 10 min or 45 min, or with U46619 for 1 h, 
no change in the content of phospho-LIMK or phospho-cofilin was observed in 
these prostate tissues (Figure 13). This may suggest that that neither 
α1-adrenoceptors nor thromboxane A2 receptors activate LIMK in the human 
prostate. 
 
Immunofluorescence study on untreated prostate tissues suggested the 
detection of phospho-cofilin (Figure 13). Although this may suggest a pool of 
active LIMK in the prostate cells, the conclusion on whether this reflects a 
constitutive or inducible process could not be drawn, as other kinases, e.g. 
TESK1 (Toshima et al., 2001a), TESK2 (Toshima et al., 2001b), and 
NRK/NESK (Nakano et al., 2003), have been also reported to be able to 
phosphorylate cofilin. LIMK may be a crucial intracellular modulator in 
prostate smooth muscle contractile response, however, the role of LIMK as a 
signal transductor from receptors to contraction in the human prostate remained 
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unclear. 
 
LIMK phosphorylate cofilin, and thereby promote actin filaments 
polymerization and cytoskeleton reorganization. Previous studies have reported 
a role of LIMKs in regulating actin organization in breast cancer cells 
(Bagheri-Yarmand et al., 2006), prostate cancer cells, and prostate epithelial 
cells (Davila et al., 2003). As observed in this study, prostate smooth muscle 
cells shown a breakdown of the actin cytoskeleton after being treated with 
SR7826 and LIMKi3 in a concentration-dependent manner, which was 
consistent with the previous findings from other cell types (Bagheri-Yarmand 
et al., 2006; Davila et al., 2003; San Martin et al., 2008; Yang et al., 1998). 
Since actin polymerization and cytoskeleton reorganization are considered to 
be a prerequisite for smooth muscle contraction, the breakdown of organization 
in WPMY-1 cells observed in this study (Figure 15) might thereby be 
responsible for reducing the smooth muscle contraction.  
 
The concentrations of both inhibitors to induce the breakdown of actin 
organization in WPMY-1 cells (5 µM) were higher than those to inhibit smooth 
muscle contraction of prostate strips (1 µM). It may be hypothesized that the 
different expression levels of LIMK1 and LIMK2 between prostate tissue and 
WPMY-1 cells might be responsible for the different required concentrations. 
As detected in this study, WPMY-1 cells showed lower mRNA contents of both 
LIMK1 and LIMK2 compared with prostate tissues. This may explain why 
higher concentrations of inhibitors were required: at low content of target 
kinases, more inhibitor may be required to effectively address the enzymes and 
thereby to attain kinase inhibition. The viability assays performed in WPMY-1 
cells may also confirm this hypothesis, as not any effect on WPMY-1 cells 
could be observed at the concentration of 1µM of SR7826 and LIMKi3. 
Reduced filaments length in some cells was observed at the concentrations of 
5µM and 10µM, i. e. turned out to occur in a concentration-dependent manner 
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(Figure 15). These findings are consistent with previous studies which reported 
reduced viability due to LMIK deficiency or after treatment of LIMK inhibitors 
in different cell types, e. g. in human Schwann cells or in mesenchymal 
glioblastoma multiforme cells (Park et al., 2014; Petrilli et al., 2014). 
 
Although α1-blockers are the first line treatment for patients with LUTS/BPH, 
their effects are still limited, approximately up to 69% of patients might not 
receive benefit fromα1-blockers (Lee et al., 2015; Matsukawa et al., 2013). It 
was hypothesized that the non-adrenergic mediators, which cause prostate 
smooth muscle tone in parallel to α1-adrenoceptors, might be responsible for 
the absent effects of α1-blockers (Hennenberg et al., 2016). It would make 
sense that if combination treatments of inhibiting adrenergic and 
non-adrenergic contractions are available, higher efficacy might therefore be 
expected.  
 
Taken together, this study may show an important role of LIMK in regulating 
smooth muscle contractile response in hyperplastic prostate. LIMK may cause 
prostate smooth muscle contraction of human prostate by phosphorylating 
cofilin and subsequent promoting actin organization in favor of the contractile 
state. Since LIMK could be involved in bladder outlet obstruction and urethral 
obstruction in BPH, it may be hypothesized that the two inhibitors studied in 
this research, SR7826 and LIMKi3, or even other LIMK inhibitors could have 
effects on improving urodynamic parameters in vivo, or releasing the 
symptoms of lower urinary tract. Although a number of previous studies 
explored the mechanisms of prostate smooth muscle contraction, and despite its 
crucial role in pathophysiology and therapy of LUTS in millions of patients, 
the understanding of prostate smooth muscle contraction is still insufficient 
(Hennenberg et al., 2014b, a; Hennenberg et al., 2017a). Further studies are still 
needed to describe its regulation and underlying mechanisms. The findings of 
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this study may thereby contribute new light, or a new model, to the 
understanding of intracellular mechanisms of prostate smooth muscle 
contraction. Also, considering the significant inhibiting effects of SR7826 and 
LIMKi3 on prostate cells and tissues, this may provide a new strategy for 
developing new therapeutic approaches for treatment of LUTS. In vivo study to 
evaluate the effects of SR7826 and LIMKi3 on improving urodynamic 
parameters may be warranted.
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6 Conclusion 
The present study suggested that LIMKs promote prostate smooth muscle 
contraction by phosphorylating cofilin and subsequent actin organization. 
LIMKs may act as important regulators in urethral obstruction and bladder 
outlet obstruction in patients with BPH/LUTS. The effects of LIMKs in the 
human prostate could be inhibited by small molecule LIMK inhibitors, SR7826 
and LIMKi3, which might therefore possibly be considered as a basis for new 
approaches in LUTS therapy. Also, a similar role of LIMK inhibitors in 
regulating smooth muscle contraction in other organs might be possible.
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7 Summary 
LUTS refer to a group of urological symptoms that are caused by multifactorial 
aetiology. The prevalence of LUTS increases with age, and will thereby lead to 
heavy economic burden for the society. In men with benign prostate 
hyperplasia, increased smooth muscle tone in the prostate could result in 
bladder outlet obstruction and subsequent symptoms of lower urinary tract. 
Pharmacological treatment aiming to inhibit prostate smooth muscle 
contraction is considered as the option of first choice. However, the efficacy of 
current available treatment options is limited, thereby, improved understanding 
in the mechanisms of prostate smooth muscle contraction and development of 
novel targets for medical therapy are warranted. Previous studies have reported 
that LIMK (LIMK1 and LIMK2) phosphorylate cofilin and act as regulators of 
actin-myosin cytoskeletal dynamics, which result in actin polymerization, 
filament assemble, and stress fiber formation in smooth muscle cells. This may 
suggest that LIMKs promote smooth muscle contraction, however, not any 
associated study has been conducted. In this project, we aimed to explore the 
effects of LIMK inhibitors on prostate smooth muscle contraction.  
 
Human prostate tissues were obtained from patients who underwent radical 
prostatectomy. RT-PCR, western blot and immunofluorescence were performed 
to detect LIMK in smooth muscle cells of prostate tissues. Phosphorylation of 
cofilin, a LIMK substrate, was detected by a phospho-specific antibody. Effects 
of LIMK inhibitors on smooth muscle contraction of prostate strips were 
performed with organ bath. 
 
Expression of LIMK in smooth muscle cells of prostate tissues was suggested 
by RT-PCR, Western blot and immunofluorescence, while higher expression 
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level of LIMK was detected in prostate tissues than that in WPMY-1 cells. Two 
LIMK inhibitors, SR7826 (1 µM) and LIMKi3 (1 µM), showed significant 
effects on inhibiting contractions of prostate strips, which were induced by the 
α1-adrenoceptor agonists, noradrenaline, phenylephrine and methoxamine, by 
the thromboxane A2 analogue, U46619, and by EFS. Reduced phosphorylation 
of cofilin in prostate tissues treated with inhibitors was observed, which 
confirmed LIMK inhibition by SR7826 and LIMKi3. In WPMY-1 cells, a line 
of cultured cells from the prostate stroma, SR7826 and LIMKi3 were observed 
to cause breakdown of actin filaments and reduced viability in a 
concentration-dependent manner. 
 
Together, this is the first study to explore the effects of small molecule LIMK 
inhibitors on regulating prostate smooth muscle contraction. The present study 
suggested that LIMKs promote prostate smooth muscle contraction by 
phosphorylating cofilin and subsequent causing actin organization, which could 
be inhibited by small molecule LIMK inhibitors, SR7826 and LIMKi3. 
Therefore, this project provides a possible novel therapy target for LUTS, 
although in vivo studies using animal models would be still warranted before 
clinical application.
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8. Zusammenfassung 
Der Sammelbegriff LUTS beschreibt eine Gruppe urologischer Beschwerden 
beim Wasserlassen mit vielfältiger Ätiologie. Ihre Prävalenz steigt mit dem 
Alter der Patientinnen und Patienten, und stellt auf Grund der demographischen 
Bevölkerungsentwicklung einen erheblichen sozioökonomischen Faktor von 
stark zunehmender Bedeutung dar. Bei Männern mit einer gutartigen 
Prostatavergrößerung (Benigne Prostatahyperplasie, BPH) führt ein erhöhter 
glattmuskulärer Tonus in der hyperplastischen Prostata häufig zu einer 
Verengung der Harnröhre und verursacht so eine Blasenauslassstörung (bladder 
outlet obstruction, BOO), und hierdurch zu Beeinträchtigungen der 
Blasenentleerung und Beschwerden beim Wasserlassen. Folglich zielen die 
Optionen der ersten Wahl zur medikamentösen Behandlung auf eine Hemmung 
der glattmuskulären Kontraktion in der Prostata ab. Die Effektivität der zur 
Verfügung stehenden Medikamente ist jedoch stark begrenzt, woraus sich ein 
dringender Bedarf an einem verbessertes Verständnis der 
Kontraktionsmechanismen und an der Identifizierung möglicher neuer 
Angriffspunkte ergibt. Verschiedene Studien zeigten, dass die LIM Kinasen 
(LIMK) über die Phosphorylierung von Cofilin in glatten Muskelzellen die 
Polymerisation von Aktin und dessen Filamentbildung fördern, was eine 
unabdingbare Voraussetzung der glattmuskulären Kontraktion darstellt. Dies 
legt zwar eine Rolle der LIMK für die glattmuskuläre Kontraktion nahe, was 
erstaunlicherweise bislang jedoch nie gezeigt wurde. In der vorliegenden Arbeit 
wurden daher die Effekte von LIMK-Inhibitoren auf die glattmuskuläre 
Kontraktion humaner Prostatagewebe untersucht. 
 
Die hier verwendeten Prostatagewebe wurden im Rahmen von 
Tumor-bedingten, radikalen Prostatektomien gewonnen. Zur Detektion einer 
ZUSAMMENFASSUNG	
75	
	
möglichen LIMK-Expression wurden RT-PCRs, Western-Blot Analysen und 
Fluoreszenz-Färbungen durchgeführt. Phosphoryliertes Cofilin wurde mit 
einem phospho-spezifischen Antikörper detektiert. Die Effekte von 
LIMK-Inhibitoren auf die Kontraktion von Prostatageweben wurden in 
myographischen Messungen in einem Organbad untersucht. Ergänzend wurden 
Untersuchungen in WPMY-1-Zellen durchgeführt, einer Zelllinie aus dem 
Stroma einer humanen Prostata. 
 
Die Ergebnisse aus RT-PCR, Western-Blot Analysen und 
Fluoreszenz-Färbungen legten eine LIMK-Expression in humanen 
Prostata-Geweben nahe, wobei LIMK1 offenbar in den glatten Muskelzellen 
des Stromas vorkommt. Diese Gewebe zeigten höhere Expressions-Level als 
WPMY-1-Zellen. Zwei strukturell unterschiedliche LIMK-Inhibitoren, SR7826 
(1 µM) und LIMKi3 (1 µM) führten zu signifikanten Hemmung der 
Kontraktion von Prostata-Geweben, welche durch die 
α1-Adrenozeptor-Agonisten Noradrenalin, Phenylephrin und Methoxamin, 
sowie durch das Thromboxan-Analogon U46619, bzw. durch Ausschüttung 
endogener Neurotransmitter nach elektrischer Feldstimulation (EFS) ausgelöst 
wurden. Die Hemmung der LIMK durch SR7826 und LIMKi3 in 
Prostatageweben wurde durch eine Verminderung der 
Cofilin-Phosphorylierung bestätigt. In WPMY-1-Zellen verursachten SR7826 
und LIMKi3 Konzentrations-abhängig einen Zusammenbruch der 
Aktin-Filamente und der Aktin-Polymerisation, sowie eine Verminderung der 
Viabilität. 
 
Dies stellt die vermutlich erste Studie dar, welche eine Hemmung der 
glattmuskulären (Prostata-)Kontraktion durch LIMK-Inhibitoren zeigt. Die 
Ergebnisse legen nahe, dass LIMK die glattmuskuläre Kontraktion in der 
Prostata antreiben, was durch eine Phosphorylierung von Cofilin und eine 
daraus resultierende Bildung oder Aufrechterhaltung von Aktin-Filamenten 
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erfolgt. Sowohl die glattmuskuläre Kontraktion als auch die Organisation der 
Aktin-Filamente ließen sich in der Prostata durch SR7826 und LIMKi3 
hemmen. Daher könnten LIM Kinasen einen neuen Angriffspunkt für mögliche 
neue LUTS-Therapien darstellen; jedoch sind in vivo Studien in Tiermodellen 
erforderlich, bevor diese Hemmstoffe in klinischen Studien verabreicht werden 
können.
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10. Abbreviations 
5-ARIs 5a-reductase inhibitors 
5-EdU 5-Ethynyl-deoxyuridine 
5-HT 5-hydroxytryptamine 
ADF Actin depolymerizing factors 
ANOVA Analysis of variance 
ATP Adenosine 5’-triphosphate 
Bim-1 Bisindolylmaleimide1 
BOO Bladder outlet obstruction 
BPH Benign prostatic hyperplasia 
CaCl2•2H2O Calcium chloride dihydrate 
cAMP Cyclic adenosine monophosphate 
CCK Cell Counting Kit 
Cdc42 Cell division cycle 42 
COX Cyclooxygenase 
CP Crossing points 
Ct Number of cycles 
DAG Diacylglycerol 
DAPI 4’,6’-diamidino-2-phenylindole-dihydrochloride 
DAPI 4’, 6’-diamidino-2-phenylindole-dihydrochloride 
DG Diacylglycerol 
DHT Dihydrotestosterone 
DMSO Dimethyl sulfoxide 
DO Detrusor overactivity 
DTT Dithiothreitol 
DU Detrusor underactivity 
EC50 Half maximal effective concentration 
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
EFS Electric field stimulation 
EP1 Prostaglandin E2 receptor subtype 1 
EP4 Prostaglandin E2 receptor subtype 4  
FAAH Fatty acid amide hydrolase 
FAK Focal adhesion kinase 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GPCR G protein-coupled receptor 
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GTPase Guanosine triphosphate kinase 
HSP Heat shock protein 
IC50 Half maximal inhibitory concentration 
IP3 Inositol 1,4,5-trisphosphate 
IPSS International Prostate Symptom Score 
KCl Potassium chloride 
KH Krebs- Henseleit solution 
KH2PO4 Potassium hydrogen phosphate 
LIMKs LIM domain kinases 
LUTS Lower urinary tract symptoms 
MAPK Mitogen-activated protein kinase 
MgCl2 Magnesium chloride 
MgSO4•7H2O Magnesium sulfate heptahydrate 
MLC Myosin light chain 
MRCK Cdc42-binding kinase 
NaCl Sodium chloride 
NaHCO3 Sodium bicarbonate 
OAB Overactive bladder 
OCT Optimal cutting temperature 
OEtA Oleoyl ethyl amide 
PAK P21-activated kinase 
PAK P21-Activated Kinase 
PBS Phosphate-buffered saline 
PBS-T Phosphate-buffered saline-Tween 
PDBu Phorbol-12,13-dibutyrate 
PDE Phosphodiesterase 
PDE4Is Phosphodiesterase 4 inhibitors 
PDE5Is Phosphodiesterase 5 inhibitors 
PEDIs Phosphodiesterase inhibitors 
PG Prostaglandin 
PK Protein kinases  
PKC Protein kinase C 
PSA Prostate-specific antigen 
PTGS Prostaglandin-endoperoxide synthase 
PVDF Polyvinylidene-Fluoride 
PVR Post-void residual 
Qmax Maximum flow rate 
RAC Ras-related C3 botulinum toxin substrate 
Rho Rhodopsin 
RhoGEF Rho guanine nucleotide exchange factor 
RNA Ribonucleic acid 
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ROCK Rhodopsin kinase 
RT Reverse Transcription 
RT-PCR Real time polymerase chain reaction 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
SFK Src family kinase 
TRPM8 Transient receptor potential melastin 8 ion channel 
TURP Transurethral resection of prostate 
TXA2 Thromboxane 
UR Urinary retention 
α1AR-blockers α1-Adrenoceptor antagonists 
β-3 agonists Beta3 adrenoceptor agonists 
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